Pharmacotherapeutic compositions for pulmonary fibrosis
A dry powder composition combining PDE3/PDE4 inhibitors and anti-fibrotic agents for direct pulmonary delivery addresses the limitations of oral treatments by enhancing lung delivery and reducing side effects, effectively managing pulmonary fibrosis.
Patent Information
- Application Number
- PCT/US2026/028420
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for pulmonary fibrosis, such as oral administration of anti-fibrotic agents like pirfenidone and nintedanib, are associated with severe side effects and low bioavailability, leading to poor patient adherence and ineffective disease management.
Development of a dry powder composition for direct pulmonary delivery comprising a combination of PDE3/PDE4 inhibitors (e.g., ensifentrine) and anti-fibrotic agents (e.g., nintedanib, treprostinil) that is stable at room temperature, moisture-resistant, and suitable for inhalation, allowing targeted delivery to the deep pulmonary tract.
The composition effectively reduces symptom severity and slows disease progression in pulmonary fibrosis, minimizing side effects and enhancing drug delivery to the lungs, thereby improving patient compliance and therapeutic outcomes.
Smart Images

Figure IMGF000021_0001 
Figure IMGF000022_0001 
Figure IMGF000022_0002
Abstract
Description
PHARMACOTHERAPEUTIC COMPOSITIONS FOR PULMONARY FIBROSISCROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U. S. Provisional application 63 / 806,565, filed on May 15, 2025, the contents of which are incorporated by reference in their entirety for all purposes.INCORPORATION BY REFERENCE
[0002] All publications, patents, and patent applications cited herein are incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event of a conflict between a term herein and a term in an incorporated reference, the term herein controls.FIELD
[0003] This disclosure provides for compositions and methods for treating incipient or moderate pulmonary fibrosis, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis (collectively pulmonary fibrosis or “PF”) in patients in need thereof. The methods described herein involve the delivery of a composition suitable for inhalation directly into the deep pulmonary tract (e.g., via a conventional delivery system such as a nebulizer, a pressurized metered dose inhaler, or a dry powder inhaler) to inhibit or slow the further development of PF, thereby maintaining or slow the loss in the quality of life and / or delaying end-of-life events for patients with PF. Left untreated, this progressive condition decreases the ability of the lungs to absorb oxygen into the blood via the alveoli, and thus leads to shortness of breath, progressive dyspnea, and a dry, nonproductive cough in the patient, all of which are characteristic of this disease. As the disease progresses, the lack of oxygen delivery via the alveoli is exacerbated leading to end-of-life for the patient unless an intervening co-morbidity is the cause of death.BACKGROUND
[0004] Pulmonary fibrosis (PF) is a disease that involves fibrotic development in the lungs, often referred to as scarring. The etiology of certain types of pulmonary fibrosis is known, whereas the etiology of idiopathic pulmonary fibrosis is unknown. Regardless, PF isa chronic lung disease characterized by increasing inflammatory infiltrates and pathological excess in collagen deposition, particularly around the alveoli. PF is often presented in patients as a non-productive cough and exertional dyspnea. The clinical course of PF is chronic, and the alteration in the structure and functionality of the lungs ultimately leads to death. PF carries a poor prognosis, with a median survival of 3.8 years among newly diagnosed adults 65 years of age or older in the United States. Despite significant improvements in the diagnosis and treatment of PF, the clinical disease prognosis has not improved.
[0005] The underlying pathology of the disease is characterized by ongoing fibrosis that includes the deep pulmonary tract containing the alveoli, leading to blockage of inhaled air from reaching the alveoli. The further the disease progresses, the greater the reduction in oxygen absorption, leading to progressive dyspnea. Ultimately, the patient’s reduced ability to obtain adequate levels of oxygen due to PF leads to comorbidities such as pulmonary hypertension, heart failure, coronary artery disease, cardiac arrhythmias, and other cardiac manifestations, which, whether alone or in combination, contribute to end-of-life for such patients. To date, there is no cure for PF.
[0006] The current treatment for PF typically includes the oral administration of anti-fibrotic agents (e.g., pirfenidone and / or nintedanib). However, such oral treatments are associated with undesirable side effects. For example, pirfenidone has been known to cause kidney and liver impairment as well as severe gastrointestinal and photosensitivity intolerance. Likewise, nintedanib can also cause severe gastrointestinal problems, including nausea, diarrhea, severe stomach pain, and weight loss, among many others. Thus, many patients have chosen either not to undergo pharmacotherapy or to cease treatment with either or both drugs due to such side effects.
[0007] Additionally, the effective oral doses are often sufficiently intolerable, precluding patients from adhering to the prescribed therapies. For example, the approved dosages for pirfenidone (having a high oral bioavailability of about 90% (with > 80% of the total dose excreted in the urine) start with an initial daily dosage of 801 mg / day broken down into either two or three capsules. This is followed by a daily maintenance dosage, after day 15, of 2,403 mg per day. On the other hand, nintedanib is administered at 150 mg twice a day but provides for only about 4.7% bioavailability due, at least in part, to its low water solubility of approximately 12 pg / mL at pH 6.8 and approximately 5 pg / mL at pH 7.4.Following first pass metabolism, each of these two drugs needs to translocate from the systemic blood flow to the alveolar epithelium, which is another major hurdle.
[0008] Cyclic nucleotides have been reported to play an essential role in PF development. Phosphodiesterases (PDEs) are important enzymes in cyclic nucleotide metabolism. Recently, PDE inhibitors, such as ensifentrine, which is commercially approved for treating COPD, have been studied as potential candidates for treating PF. WO 2024 / 084212 reported that in rats with bleomycin-induced PF, inhalation of ensifentrine, a combined PDE3 / PDE4 inhibitor, appears superior to oral administration of nintedanib.
[0009] Accordingly, there remains an unmet medical need for a more effective and well-tolerated pharmacotherapeutic approach to treating PF and preventing or slowing its progression.SUMMARY
[0010] This disclosure provides pharmaceutical compositions for treating PF. In some embodiments, the composition for treating PF is a dry powder composition suitable for direct pulmonary delivery, including delivery to the deep pulmonary tract. This dry powder is characterized, in part, by being room temperature stable (e.g., having a desirable shelf life at room temperature or at temperature). It is also contemplated that this dry powder would be moisture -resistant. Direct pulmonary delivery is used synonymously with oral inhalation.
[0011] In one aspect, this disclosure provides for a dry powder composition suitable for direct pulmonary delivery, which comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent. Suitable PDE3 / PDE4 inhibitors for use in such compositions include, by way of example only, ensifentrine, HS K39004 / ANO 1, HRS-9821 / GSK6582701, and TQC3721.
[0012] In one aspect, this disclosure provides for a dry powder composition suitable for direct pulmonary delivery, which comprises ensifentrine or a pharmaceutically acceptable salt thereof and an anti-fibrotic agent.
[0013] In one aspect, this disclosure provides for a dry powder composition suitable for direct pulmonary delivery, which comprises HSK39004 / AN01 or a pharmaceutically acceptable salt thereof and an anti-fibrotic agent.
[0014] In one aspect, this provides for a dry powder composition suitable for direct pulmonary delivery, which comprises HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof and an anti-fibrotic agent.
[0015] In one aspect, this provides for a dry powder composition suitable for direct pulmonary delivery, which comprises TQC3721 or a pharmaceutically acceptable salt thereof and an anti-fibrotic agent.,
[0016] In one aspect, the anti-fibrotic agent is selected from nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, and pirfenidone or a pharmaceutically acceptable salt of each of these. Combinations of two or more of these anti-fibrotic agents are included herein.
[0017] In one aspect, the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is nintedanib or a salt thereof.
[0018] In one aspect, the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is treprostinil or a salt thereof.
[0019] In one aspect, the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is treprostinil palmitil.
[0020] In one aspect, the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is treprostinil sodium.
[0021] In one aspect, the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is pirfenidone.
[0022] In one aspect, the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is deupirfenidone.
[0023] In one aspect, the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is nintedanib or a pharmaceutically acceptable salt thereof.
[0024] In one aspect, the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is treprostinil or a pharmaceutically acceptable salt thereof.
[0025] In one aspect, the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is treprostinil palmitil.
[0026] In one aspect, the PDE3 / PDE4 inhibitor is HSK39004 / AN01 and the anti-fibrotic agent is treprostinil sodium.
[0027] In one aspect, the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is pirfenidone.
[0028] In one aspect, the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is deupirfenidone.
[0029] In one aspect, the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is nintedanib or a pharmaceutically acceptable salt thereof.
[0030] In one aspect, the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is treprostinil or a pharmaceutically acceptable salt thereof.
[0031] In one aspect, the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is treprostinil palmitil.
[0032] In one aspect, the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is treprostinil sodium.
[0033] In one aspect, the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is pirfenidone.
[0034] In one aspect, the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is deupirfenidone.
[0035] In one aspect, the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is nintedanib or a pharmaceutically acceptable salt thereof.
[0036] In one aspect, the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is treprostinil or a pharmaceutically acceptable salt thereof.
[0037] In one aspect, the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is treprostinil palmitil.
[0038] In one aspect, the PDE3 / PDE4 inhibitor is TQC3721 and the anti -fibrotic agent is treprostinil sodium.
[0039] In one aspect, the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is pirfenidone.
[0040] In one aspect, the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is deupirfenidone.
[0041] In one aspect, provided is a dry powder composition comprising an effective amount of a) PDE3 / PDE4 inhibitor selected from ensifentrine, HSK39004 / AN01, HRS-9821 / GSK6582701, and TQC3721, each optionally as a pharmaceutically acceptable salt, and b) an effective amount of an anti-fibrotic agent or a pharmaceutically acceptable salt thereof, wherein the composition is suitable for administration by inhalation.
[0042] In one aspect, the dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc: or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0043] In one aspect, the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm or from about 0.5 pm to about 10 pm; or from about 0.5 to about 5 pm.
[0044] In one aspect, when the dry powder compositions described herein have a bulk density of from about 0.03 g / cc to about 0.15 g / cc or about 0.04 g / cc to about 0.11 g / cc, such are considered to be ultra-low density dry powders. In another aspect, these ultra-low density powder compositions, which are thermal stable and are contemplated to be moisture stable, comprise particles having a size of from about 0.5 pm to about 10 pm; or from about 0.5 to about 5 pm. The combination of ultra-low densities and particle sizes allows for entrainment in the airflow upon slow and deep inhalation of the particles, which allows for penetration of more medicaments into the deep pulmonary tract.
[0045] In one aspect, the dry powder as described herein comprises no more than about 6 weight percent water or no more than about 4 weight percent water.
[0046] In one aspect, the dry powder composition further comprises: c) a lecithin compound such as a di-fatty acid phosphatidylcholine, and d) a divalent cation (e.g., from calcium or magnesium chloride).
[0047] In one aspect, the anti-fibrotic agent is selected from nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, pirfenidone, or deupirfenidone, or a pharmaceutically acceptable salt of each of these as is appropriate.
[0048] In one aspect, the anti-fibrotic agent is nintedanib.
[0049] When so used, the relative weight ratio of a) ensifentrine (independent of the salt if administered as a pharmaceutically acceptable salt) to b) nintedanib (also independent of the salt if administered as a pharmaceutically acceptable salt) is from about 0.125:1 to about 5:1 (about 1:8 to about 5:1).
[0050] In one aspect, when used as a pharmaceutically acceptable salt, the salt is nintedanib esylate; and, when used as a pharmaceutically acceptable salt, the salt of ensifentrine is ensifentrine hydrochloride.
[0051] In one aspect, there is provided a dry powder composition which comprises a) ensifentrine or a pharmaceutically acceptable salt thereof, and b) nintedanib or a pharmaceutically acceptable salt thereof,wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc;wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm or from about 0.5 to about 10.0 pm; or from about 0.5 to about 5.0 pm;wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1 or about 1:4 to 5:1 (e.g., about 3:8, or about 5:8, or about 1: 1, or about 4:1), where the weight of each is based on the free base thereof; and further wherein the dry powder as described herein comprises no more than about 6 weight percent water or no more than about 4 weight percent water.
[0052] In one aspect, the compositions described herein are provided in a device suitable for administration by inhalation. Such devices include, by way of example only, a nebulizer, a pressurized metered dose inhaler (pMDI), or a dry powder inhaler (DPI). In one aspect, both ensifentrine and nintedanib are uniformly dispersed throughout the dry powder that is loaded into the device.
[0053] In one aspect, there is provided a dry powder composition comprising both ensifentrine and nintedanib or pharmaceutically acceptable salts thereof, wherein said composition is suitable for direct pulmonary administration, wherein said dry powder composition further comprises:a) an effective amount of distearoylphosphatidylcholine; andb) an effective amount of magnesium chloride or calcium chloride;wherein said dry powder composition comprises particles having a median particle size of from about 0.5 to about 15 pm; from about 0.5 to about 10 pm; or from about 0.5 to about 5 pm;wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1 or about 1:5 to 5:1 (e.g., about 3:8, or about 5:8, or about 1: 1, or about 4:1) where the weight of each is based on the free base thereof; andwherein said dry powder has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, from about 0.04 g / cc to about 0.11 g / cc, from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc; andfurther wherein said dry powder composition has a water content of no more than about 6 weight percent water.
[0054] The addition of a di-fatty acid phosphatidylcholine (e.g., distearoylphosphatidylcholine) provides for a coating over the medicaments, allowing the dry powder to be encapsulated into an ampoule or capsule (e.g., size 3), which is suitable for use in a conventional dry powder inhaler. When not using a low-resistance device, slow and deep inhalation at a flow rate of from about 25 to about 35 liters per minute (LPM) results in an increase in the amount of medicaments delivered into the lung. When coupled with the use of ultra-low-density powders having suitable diameters, more of the medicament will reach the deep pulmonary tract. In turn, as the amount of medicament in the deep pulmonary tract per administration increases, a corresponding reduction in the dose of each drug is permitted to achieve a therapeutic result. Moreover, the approach described herein avoids oral administration of these drugs, as well as the acute side effects that can arise from the high systemic exposure required to achieve therapeutic concentrations in vivo.
[0055] In one aspect, the compositions comprising both ensifentrine or a pharmaceutically acceptable salt thereof and nintedanib or a pharmaceutically acceptable salt thereof further comprisec) an effective amount of distearoylphosphatidylcholine; andd) an effective amount of magnesium chloride or calcium chloride.
[0056] In one aspect, the dry powder composition can further comprise one or more pharmaceutically acceptable additives, selected from a dispersing agent, a buffering agent, a disaccharide, an antioxidant, a stabilizer, and any combination thereof. The dispersing agent can be selected from leucine, trileucine, and a combination of leucine and trileucine, and each or any combination of such agents can optionally include a further dispersing agent. The dispersing agent can be polyethylene glycol sorbitan monooleate. The buffering agent can be a biocompatible buffer, optionally an acetate, citrate, phosphate, tartrate, and / or triethanolamine buffer. The disaccharide can be trehalose or lactose (anhydrate or monohydrate). The antioxidant can be selected from ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, cysteine, glutathione, propyl gallate, sodium metabisulfite, sodiumthiosulfate, and vitamin E. Also provided is a bulk composition comprising the dry powder composition described herein and at least one container.
[0057] In a further aspect, provided is a method for treating a patient diagnosed with pulmonary fibrosis (PF), which method comprises:administering to the lungs of the patient a dry powder composition comprising an effective amount of a) PDE3 / PDE4 inhibitor or a pharmaceutically acceptable salt thereof, and b) an effective amount of an anti-fibrotic agent or a pharmaceutically acceptable salt thereof, wherein the composition is suitable for administration by inhalation,wherein said PF is selected from an interstitial lung disease, a progressive fibrosing interstitial lung disease, a systemic sclerosis-associated interstitial lung disease, an idiopathic pulmonary fibrosis, and pulmonary fibrosis.
[0058] In one aspect, the PF is idiopathic pulmonary fibrosis.
[0059] In one aspect, the dry powder composition has a bulk density of from about0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0060] In one aspect, the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm or from about 0.5 to about 10 pm; or from about 0.5 to about 5 pm.
[0061] In one aspect, the dry powder as described herein comprises no more than about 6 weight percent water or no more than about 4 percent water.
[0062] In one aspect, the dry powder composition further comprises: c) a lecithin compound such as a di-fatty acid phosphatidylcholine, and d) a divalent cation (e.g., calcium or magnesium chloride).
[0063] In one aspect, the anti-fibrotic agent is selected from nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, pirfenidone, and deupirfenidone, or a pharmaceutically acceptable salt of each of these. Combinations of two or more of these anti-fibrotic agents are included herein.
[0064] In one aspect, there is provided a method for treating a patient diagnosed with stage 1 or stage 2 pulmonary fibrosis (PF), which method comprises:administering an effective amount of the dry powder composition described herein to the lungs of said patient,wherein the step of administering to the patient is a sequential or contemporaneous administration in any order of ensifentrine or a pharmaceutically acceptable salt thereof and a second anti-fibrotic agent selected from an effective amount of nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, pirfenidone, and deupirfenidone, or a pharmaceutically acceptable salt of each of these;wherein said dry powder composition comprises particles having a median particle size of from about 0.5 to about 15 pm; or from about 0.5 to about 10.0 pm; or from about 0.5 to about 5.0 pm;wherein such compositions employ a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.04 g / cc to about 0.10 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc; andwherein said PF is idiopathic pulmonary fibrosis (IPD), interstitial lung disease, progressive fibrosing interstitial lung disease, or systemic sclerosis-associated interstitial lung disease.
[0065] In one aspect, the patient may first be qualified as having stage 1 or stage 2 PF. The patient may qualify as having incipient (stage 1) or moderately developed (stage 2) idiopathic pulmonary fibrosis, but is not diagnosed with hypoxic respiratory failure or resting hypoxemia (stages 3 and 4).
[0066] The compositions and methods described herein can stabilize the patient’s symptoms associated with PF and / or mitigate the rate of increased symptom severity associated with PF in treated patients, including coughing, compromised carbon monoxide diffusion capacity, stabilization of dyspnea, and reduced periods of shortness of breath. The patient with PF can have a forced vital capacity (FVC) of more than about 40% ± 5% and / or a DLCO (lung diffusion capacity for carbon monoxide) of more than about 30% ± 5% predicted. The effective amount of the pharmaceutical combination can reduce either the symptoms and / or the rate of disease progression in said patient by at least about 10%, about 20%, about 30%, about 50%, or about 75%. In the methods described herein, ensifentrine or the pharmaceutically acceptable salt thereof can be dosed at about 0.5 mg to about 5 mg ensifentrine, administered twice daily; and nintedanib or the pharmaceutically acceptable salt thereof can be dosed at about 1 mg to about 8 mg nintedanib, administered twice daily. It is understood that dosing of both ensifentrine and nintedanib is based on the free base.
[0067] In addition, when the anti-fibrotic agent is nintedanib or a pharmaceutically acceptable salt thereof, the compositions and methods described herein can reduce theseverity and / or frequency to at least one adverse symptom associated with the oral administration of nintedanib or the pharmaceutically acceptable salt thereof. The at least one adverse event associated with the oral administration of nintedanib or the pharmaceutically acceptable salt thereof can be selected from the group consisting of: nausea, a rash, stomach pain, an upper respiratory tract infection, diarrhea, fatigue, a headache, indigestion, dizziness, decreased patient appetite or loss of appetite, gastroesophageal reflux disease (GERD), sinusitis, sleeplessness, weight loss, and joint pain.
[0068] In one aspect, the use of ultra-low-density dry powder composition delivered from the inhalation dispenser into the airways of the lungs allows for a major portion of the composition to be directed to the deep pulmonary tract.
[0069] In one aspect, the use of ultra-low-density dry powder compositions having a bulk density of from about 0.03 g / cc to about 0.15 g / cc can enhance the amount of drug delivered to the deep pulmonary tract of the lungs.
[0070] In yet another aspect, provided is a method for qualifying a patient for treatment of pulmonary fibrosis (PF), which method comprises:a) evaluating said patient to determine the stage of PF for that patient;b) qualifying a patient for treatment who is evaluated as having stage 1 or stage 2 PF;c) disqualifying a patient from said treatment if said patient is diagnosed as having stage 3 or stage 4 PF;d) initiating treatment of said qualified patients with a dry powder composition comprising ensifentrine or the pharmaceutically acceptable salt and an anti-fibrotic agent selected from an effective amount of nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, pirfenidone, and deupirfenidone, or a pharmaceutically acceptable salt of each of these;e) monitoring said qualified patient before and after treatment is initiated to determine the extent of progression of said disease in each of said patients after initiating pharmacotherapy as compared to prior to treatment and determining whether an inflection point is identified, evidencing that the slope in the rate of disease progression has changed from a higher angle on the X and Y axis to a lower angle; andf) optionally removing patients from pharmacotherapy for whom the attending clinician determines that further treatment is no longer effective.
[0071] Also provided is a method for treating qualified patients diagnosed with pulmonary fibrosis (PF), which method comprises:a) initiating pharmacotherapy comprising administering said dry powder composition as described herein in a therapeutic amount to the patient qualified as having stage 1 or stage 2 PF;b) maintaining said pharmacotherapy until the attending clinician determines that the disease progression in the patient has evolved such that there is no longer a benefit to the patient; andc) terminating said pharmacotherapy.
[0072] Further provided is a method of making a dry powder composition comprising i) ensifentrine or a pharmaceutically acceptable salt thereof and ii) an anti-fibrotic agent or a pharmaceutically acceptable salt thereof, said method comprises:a) preparing a nanoemulsion comprising perfluorooctyl bromide (PFOB) droplets, wherein the emulsion is stabilized by distearoylphosphatidylcholine (DSPC),b) admixing i) ensifentrine or a pharmaceutically acceptable salt thereof, and ii) an anti-fibrotic agent while maintaining the water present in a water phase in the nanoemulsion at a temperature of below about 40 °C, wherein the nanoemulsion comprises about 90% water, andc) spray drying the nanoemulsion to obtain the powder composition.
[0073] In one aspect, the anti-fibrotic agent is selected from an effective amount of nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, pirfenidone, and deupirfenidone, or a pharmaceutically acceptable salt thereof.
[0074] In one aspect, the anti-fibrotic agent is nintedanib, which is used as either the free base or as a salt such as the esylate salt.
[0075] Alternatively, a first dry powder comprising a PDE3 / PDE4 inhibitor selected from ensifentrine, HSK39004 / AN01, HRS-9821 / GSK6582701, and TQC3721, each optionally as a pharmaceutically acceptable salt, is prepared. A second dry powder comprising an anti-fibrotic agent as described here is also prepared. These two powders are then combined in appropriate amounts such that the ratio of PDE3 / PDE4 inhibitor to the anti-fibrotic agent is within the ratios provided herein. The resulting combination of dry powders can then be delivered to the patient by direct pulmonary delivery. Still further, each of the first and second dry powders can be administered separately by direct pulmonary delivery either contemporaneously or sequentially.
[0076] In one aspect, also provided herein is a dry powder composition comprising a PDE3 / PDE4 inhibitor or pharmaceutically acceptable salt thereof, which dry powder composition comprises:an inhibitor is selected from HSK39004 / AN01, HRS-9821 / GSK6582701, and TQC3721, each optionally as a pharmaceutically acceptable salt thereof, wherein said inhibitor is the sole PF medicament therein;wherein said dry powder composition comprises particles having a median particle size of from about 0.5 to about 15 pm; or from about 0.5 to about 10 pm; or from about 0.5 to about 5 pm;a bulk density of from about 0.03 g / cc to about 0.15 g / cc, from about 0.04 g / cc to about 0.11 g / cc, from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc;wherein said dry powder composition has a water content of no more than about 6 weight percent water; andfurther wherein said composition is suitable for treating PF.
[0077] In one aspect, said dry powder composition further comprises an effective amount of distearoylphosphatidylcholine and an effective amount of magnesium chloride or calcium chloride.
[0078] In one aspect, also provided herein is a dry powder composition comprising an anti-fibrotic agent or a pharmaceutically acceptable salt thereof, which dry powder composition comprises:an anti-fibrotic agent selected from nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, pirfenidone, and deupirfenidone, or where appropriate, a pharmaceutically acceptable salt thereof, wherein said anti-fibrotic agent is the sole PF medicament therein;wherein said dry powder composition comprises particles having a median particle size of from about 0.5 to about 15 pm; or from about 0.5 to about 10 pm; or from about 0.5 to about 5 pm;a bulk density of from about 0.03 g / cc to about 0.15 g / cc, from about 0.04 g / cc to about 0.11 g / cc, from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc;wherein said dry powder composition has a water content of no more than about 6 weight percent water; andfurther wherein said composition is suitable for treating PF.
[0079] In one aspect, said dry powder composition further comprises an effective amount of distearoylphosphatidylcholine and an effective amount of magnesium chloride or calcium chloride.
[0080] When nintedanib is used as the anti-fibrotic agent, the method may further comprise adjusting the pH of the admixed nanoemulsion to about 5.3 ± 0.3, and wherein nintedanib or the pharmaceutically acceptable salt thereof is admixed in the emulsion first, followed by admixing ensifentrine or the pharmaceutically acceptable salt thereof.BRIEF DESCRIPTION OF THE FIGURES
[0081] The accompanying drawings are not intended to be drawn to scale. The drawings are illustrative only and should not be interpreted to limit any one claim. Not every component may be labeled in every drawing.
[0082] Figure 1 illustrates the particle size distributions of several compositions of Example 1.
[0083] Figure 2 illustrates the X-ray powder diffraction patterns of spray-dried dry powders of Example 7. Patterns have been vertically offset for clarity.
[0084] Figure 3 illustrates the X-ray powder pattern of spray -dried Composition A with the pattern for ensifentrine overlayed for reference (dashes).
[0085] Figure 4 illustrates the X-ray powder pattern of spray -dried Composition B (dashes) with the pattern for nintedanib esylate (black lines) and nintedanib base (dots) overlayed for reference.
[0086] Figure 5 illustrates the X-ray powder pattern of Figure 4 magnified 20 times.
[0087] Figure 6 illustrates the X-ray powder pattern of spray -dried Composition C with the pattern for nintedanib free base overlayed for clarity.
[0088] Figure 7 illustrates the X-ray powder patterns of spray-dried Composition D with the patterns for ensifentrine and nintedanib free base overlayed for clarity.
[0089] Figure 8 illustrates the X-ray powder patterns of spray-dried Composition E, wherein ensifentrine is provided for reference.
[0090] Figure 9 illustrates the low-angle region of the X-ray powder patterns of spray-dried powder Composition F, wherein ensifentrine and nintedanib free base patterns are provided for reference.
[0091] Figure 10 illustrates the low-angle region of the X-ray powder patterns of spray-dried powder Composition G with patterns for ensifentrine and nintedanib esylate provided for reference.
[0092] Figure 11 illustrates a compilation of Figures 7-10.
[0093] Figure 12 illustrates key aerosol performance metrics for Compositions D andF.
[0094] Figure 13 illustrates the retention of the E: N ratio throughout for Compositions D-G.
[0095] Figure 14 illustrates the stability results of Example 14.
[0096] Figure 15 illustrates a bar graph showing aPSD mass (pg) per device / stage forComposition F (Nintedanib-only view) (n=4) as described in Example 13.
[0097] Figure 16 illustrates a bar graph showing aPSD mass (µg) per device / stage for Composition F (Ensifentrine-only view) (n=4) as described in Example 13.
[0098] Figure 17 illustrates a bar graph showing aPSD mass (pg) per device / stage for Composition D (Nintedanib-only view) (n=4) as described in Example 13.
[0099] Figure 18 illustrates a bar graph showing aPSD mass (pg) per device / stage for Composition D (Ensifentrine-only view) (n=4) as described in Example 13.DETAILED DESCRIPTION
[0100] Disclosed are compositions and methods for treating incipient or moderate pulmonary fibrosis, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis (collectively pulmonary fibrosis or “PF”) in patients in need thereof. Prior to describing the compositions and methods in more detail, the following terms will be defined.Acronyms and DefinitionsAIT Alberta idealized throatAPI Active pharmaceutical ingredientaPSD Aerodynamic particle size distributionBID bis in die, medication taken twice a daycc or cm3 cubic centimeterCDMO Contract development and manufacturing organizationCOPD Chronic obstructive pulmonary diseaseCQA Critical quality attributeCSFIR Colony-stimulating factor 1 receptorDLCO Lung diffusion capacity for carbon monoxideDIT Dryer inlet temperatureDOT Dryer outlet temperatureDPI Dry powder inhalerDSC Differential scanning calorimetryDSPC DistearoylphosphatidylcholineDVS Dynamic vapor sorptionFEV1 Forced Expiratory Volume in 1 secondFlurry Flurry Powders LLCFVC Forced Vital CapacityGERD Gastrointestinal reflux diseaseg Gram (when associated with a number)g / min Grams per minuteGLP Good laboratory practicesGMP Good manufacturing practicesgPSD Geometric particle size distributioniBCS inhalation-based biopharmaceutics classification system IPD Idiopathic pulmonary fibrosisIPFi Incipient pulmonary fibrosis (aka Stage 1)kPa KilopascalLPM Liters per minutemg Milligrams when associated with a numbermin, Min, or min. minutes when associated with a numbermL Milliliters when associated with a numberNES Nintedanib esylatePAH Pulmonary arterial hypertensionPC PhosphatidylcholinePDE PhosphodiesterasePDGFR alpha / PDGFR a Platelet-derived growth factor receptor- aPDGFR beta / PDGFR Platelet-derived growth factor receptor-PPF Pulmonary fibrosisPFOB perfluorooctyl bromidePH-ILD pulmonary hypertension in interstitial lung disease pMDI pressurized metered-dose inhalersPPF progressive pulmonary fibrosisppb parts per billionrpm rotations per minutes seconds (when associated with a number)SCFR stem cell growth factor receptor kinasesSDP Spray dried powderSM Suspension mediumTBD To be determinedTGF- tissue growth factor betaTm Melt transition temperatureTOC Total organic carbonTPP Target product profilePg Micrograms when associated with a numberpL or pl Microliters when associated with a numberpm Micrometers (or microns) when associated with a number wt% Weight personXRPD X-ray powder diffraction6MWT 6 minute walk test
[0101] The following definitions provide clarity to certain terms and phrases used in this application. It is understood that terms or phrases used herein that are not defined have their accepted medical or biological meaning.
[0102] The term “dry powder” refers to a powder that possesses a moisture content that allows the powder to remain chemically and physically stable during storage at ambient temperature, and is easily dispersible. In some embodiments, the dry powders disclosed herein will have no more than about 6 weight percent of water or no more than about 4 weight percent water in the dry powder as determined by the weight differential of the dry powder before and after desiccation. In some embodiments, the amount of water in said dry powder is from about 0.2 to about 4 weight percent water also as determined in this manner, application. It is understood that terms or phrases used herein that are not defined have their accepted medical or biological meaning.
[0103] As used herein, the term “density” refers to “bulk density” unless the context indicates otherwise.
[0104] The term “suspension medium” refers to certain fluids which, when combined with water and a distearoylphosphatidylcholine or other di-fatty phosphatidylcholine, form a stable emulsion to which the active(s) and calcium dichloride can be added. In this regard, such suspension media include those set forth in US Patent No. 9,554,993, which is incorporated herein by reference in its entirety.
[0105] The term “administering” or “administration” or “administer” means to dispense, provide, and / or apply, and refers to any route for respiratory inhalation administration. For example, administering can refer to respiratory inhalation administration, such as oral inhalation and nasal inhalation. In some embodiments, respiratory inhalation is oral inhalation.
[0106] The term “combination therapy” refers to a therapeutic method involving two or more different treatments, often two or more different medications, to treat a single condition. In a combination therapy, two or more medications can be administered sequentially or contemporaneously (simultaneously) in one or more units.
[0107] The term “reduction” or “reducing” refers to the extent to which a composition, as described herein, impacts either a) the progression in patients with stage 1 or stage 2 PF so treated compared to patients not so treated where both sets of patients started at an equivalent point in time relative to disease progression, and / or b) the extent of symptoms experienced by the treated patients with stage 1 or stage 2 PF as compared to untreatedpatients where both sets of patients started at an equivalent point in time relative to disease progression. In some embodiments, the reduction in the rate of disease progression can be at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 75%, for treated patients to reach a certain milestone in disease progression as compared to equivalent patients who are untreated with the compositions described herein. It is understood that this rate of disease progression is an average of treated patients, which is compared against an average of untreated patients. In some instances, it is contemplated that for two cohorts of an equivalent number of treated and untreated patients at an equivalent stage of moderate disease progression, untreated patients at stage 2 may arrive at stage 3 in 24 months, whereas the treated patients would arrive at that stage in 26.4 months (10% reduction), or in 28.8 months (20% reduction) or in 36 months (50% reduction) to reach that milestone point in disease progression.
[0108] The term “patient” and “subject” are used herein interchangeably and refer to any animal (e.g., a mammal, such as a human, a laboratory animal, such as a mouse, rat, rabbit, guinea pig, or other animal models of idiopathic pulmonary fibrosis, or a domesticated animal, such as a dog, cat, or a domesticated animal, for example, sheep, horses, cattle, pigs and goats). A subject in need of treatment, according to the methods described herein, may be one who has been diagnosed with incipient, mild, or moderate PF.
[0109] The term “pharmaceutically acceptable salts” is meant to include salts of the compounds listed herein, which are prepared with relatively non-toxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds described herein contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Non-limiting examples of salts derived from pharmaceutically acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N. N’-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine,trimethylamine, tripropylamine, tromethamine and the like. When compounds described herein contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively non-toxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like. See, e.g., Berge, S. M., et al., “Pharmaceutical Salts” J. Pharm. Sci., 1977, 66(1): 1-19; see also P. H. Stahl and C. G. Wermuth, editors, Handbook of Pharmaceutical Salts: Properties, Selection and Use, Weinheim / Zurich: Wiley-VCH / VHCA, 2002; the disclosure of each of which is incorporated herein by reference in its entirety.
[0110] The terms “therapeutically effective amount” and “pharmaceutically effective amount” refer to a non-toxic but sufficient amount of a composition as described herein to provide the desired biological result(s), and / or to an amount sufficient to carry out a specifically stated purpose.
[0111] The terms “treatment”, “treating”, “treatment of’, and other grammatical uses of “treat” refer to an approach for obtaining beneficial or desired results, including clinical results with patients suffering from Stage 1 or Stage 2 PF. Beneficial or desired clinical results can include, but are not limited to, one or more of the following: a) stabilization in one or more symptoms; b) stabilization of the condition, disorder or disease; c) at least a partial delay or slowing of a condition, disorder, or disease progression; and d) at least partially delay or slowing the progression of at least one symptom associated with the disease. The treatment may results in a reduction of either a) the progression in patients with stage 1 or stage 2 PF so treated compared to patients not so treated where both sets of patients started at an equivalent point in time relative to disease progression, and / or b) the extent of symptoms experienced by the treated patients with stage 1 or stage 2 PF as compared to untreated patients where both sets of patients started at an equivalent point in time relative to diseaseprogression, as described above. Methods for determining the result of a treatment are known in the art.
[0112] As used herein, when a range is described, that range includes both the endpoints of the range as well as all numbers in between. For example, “between 1 mg and 10 mg” includes 1 mg, 10 mg and all 0.1 mg amounts between 1 mg and 10 mg. In some embodiments, the amounts included in such ranges are rounded to two decimal points when the recited value is defined in 3 or more decimal points or to one decimal point when the recited value is defined in 2 or more decimal points. For example, rounding to two decimal points would entail that any value in the third decimal point that is less the “5” is lowered to the two decimal point value recited, and any value in the third decimal point which is “5” or higher raises the value of the second decimal point to the next higher number.
[0113] As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well unless the context clearly indicates otherwise.
[0114] As used herein, the term “about” when used before a numerical designation, e.g., temperature, time, amount, concentration, and such other, including a range, indicates approximations that may vary by ( + ) or ( - ) 10%, 5%, 1%, or any subrange or a sub value therebetween. In some embodiments, the term “about” when used with regard to a dose amount means that the dose may vary by ± 10%.
[0115] As used herein, “direct pulmonary delivery” is synonymous with “oral inhalation.”
[0116] As used herein, the term “deep pulmonary tract” refers to the tissue (including interstitium) adjacent to or proximate to the alveoli in the lungs, which, correspondingly, will be proximate to the fibrotic tissue.
[0117] As used herein, the terms “contemporaneously” and “simultaneously” and words associated therewith as they relate to the time differential between dosing a patient with first medicament by inhalation (e.g., a first dry powder) followed by dosing the same patient by the same route of inhalation with a second medicament (e.g., a second dry powder) is sufficiently short such that the two medicaments behave in vivo as though these medicaments were taken simultaneously. In general, when both medicaments are administered by the same route of inhalation within about 5 minutes of each other, then these two administrations are considered to be contemporaneous. In some cases, it may be desirable to have both medicaments administered within about 3 minutes.
[0118] As used herein, the term “sequential" as it relates to the time differential between dosing a patient with first medicament by inhalation (e.g., a first dry powder) followed by dosing the same patient by the same route of inhalation with a second medicament (e.g., a second dry powder). If the time differential is longer than about 5 minutes, these two administrations are considered to be sequential.
[0119] As used herein, the term “comprising" or “comprises" is intended to mean that the compositions and methods include the recited elements but do not exclude other nonrecited elements.
[0120] As used herein, the term “consisting essentially of’ when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed disclosure.
[0121] As used herein, the tern “consisting of’ shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this disclosure.
[0122] As used herein, the term “propellant” refers to conventional agents used to deliver the dry powder composition from a conventional dispenser, such as an MDI inhaler (available from conventional commercial sources), into the deep pulmonary tract, with an efficacious portion being delivered to the alveoli and adjacent tissue.
[0123] As used herein, the term “ensifentrine” refers to (A-(2-{(2E)-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-6,7-dihydro-2H-pyrimido[6,l-fl]isoquinolin-3(4 / 7)-yl}ethyl)urea (also known as RPL554) represented by formula I:Ensifentrine, as a combined phosphodiesterase 3 / 4 (PDE3 / PDE4) inhibitor, has both bronchodilatory and anti-inflammatory activities. Ensifentrine has been approved for the treatment of chronic obstructive pulmonary disease (COPD) in adults. Pharmaceutical salts of ensifentrine include, for example, ensifentrine hydrochloride, ensifentrine ethane-1,2-disulfonate, and other salts described in U. S. Patent No. 10,463,665.
[0124] As used herein, the term “HSK39004 / AN01” refers to a PDE3 / PDE4 active compound closely related structure to ensifentrine which contains a deuterated methoxy group instead of a methoxy group, as shown below in Formula IA:
[0125] As used herein, the term “HRS-9821 / GSK6582701” refers to a PDE3 / PDE4 active compound closely related structure to ensifentrine which contains a cyclic urea (imidazolidinone) group instead of a urea group, as shown below in formula IB:
[0126] As used herein, the term “TQC3721” refers to a PDE3 / PDE4 active compound closely related structure to ensifentrine, as shown below in formula IC:
[0127] As used herein, the term “nintedanib” refers to a compound represented by formula II and salts thereof. The term “nintedanib esylate” refers to the esylate salt as per formula II-A:
[0128] As used herein, the term “treprostinil” refers to a compound represented by formula III:which includes pharmaceutically acceptable salts thereof. “Treprostinil sodium” refers a compound represented by formula III-A:
[0129] As used herein, the term “treprostinil palmitil” refers to a compound represented by formula IV:
[0130] As used herein, the term “pirfenidone” refers to a compound represented by formula V:as well as its tautomeric structure V-A:
[0131] Each of the above compounds includes the deuterated version thereof, wherein a methyl group and / or a methylene group can have some or all of the hydrogen atoms replaced by deuterium as well as wherein some or all of the aromatic or heteroaromatic hydrogen atoms are replaced by a deuterium group. For example, the term also encompasses deuterated forms of pirfenidone (e.g., deupirfenidone (LYT-100) developed by PureTech). Pirfenidone is not considered to have a salt form.
[0132] As to PF, clinicians have categorized the progression of the disease into 4 stages based on the conditions of the patient. Specifically, Stage 1 refers to patients who meet the following criteria:Stage 1: Recently diagnosed
[0133] As used herein, the term “incipient PF” is synonymous with Stage 1 PF and refers to patients who are first diagnosed with PF and the patient has early symptoms of PF such as one or more fatigue, shortness of breath, and a distinctive, dry cough; and whentested for Pulmonary Function or Lung Function Tests does not require oxygen at this stage of PF, either while resting or during limited activity.Stage 2 (or Moderate PF): Oxygen is needed only with Activity
[0134] As used herein, the term “moderate PF” is synonymous with Stage 2 PF and refers to patients diagnosed with PF who experience coughing more frequently, in addition to shortness of breath with activity, and who is prescribed the use of oxygen at this stage especially during limited activity. Some patients at this stage can use a pulse oximeter.Stage 3 (or Severe PF): Needs oxygen throughout the day
[0135] As used herein, the term “severe PF” is synonymous with Stage 3 PF and refers to patients diagnosed with PF where the progress of the disease is characterized clinically as Stage 3 or Stage 4 based on their oxygen requirements. A patient is characterized as having Stage 3 PF if that patient feels shortness of breath with and without activity and experiences low oxygen levels at rest. Cough and fatigue at this stage are common and bothersome. Patients at this stage require oxygen throughout the day.Stage 4: Advanced oxygen needs
[0136] As PF progresses, Stage 4 is reached when a portable oxygen delivery system is no longer sufficient for a patient’s needs, and the patient is placed on a high-flow oxygen delivery device. At this stage, the disease is approaching the terminal stage, and very little in the way of therapy is available to ameliorate the patient’s condition.
[0137] Classification of PF may also or alternatively be based on FEV 1 (Forced Expiratory Volume in 1s), FVC (forced vital capacity), and an indirect measure referred to as 6 min walk test (6MWT).
[0138] As used herein, the term “uniform” or “uniformly” as used herein to describe the concentration of each anti-fibrotic agent in the dry powder composition is substantially the same (within ± 10%; preferably within ± 5%; and more preferably within ± 1%) of the average composition found for the entirety of the composition when different portions of the composition are tested for the concentration of actives therein.
[0139] As used herein, the term “di-fatty acid phosphatidylcholine” means that the alpha and beta hydroxy groups of glycerol are substituted with two fatty acid esters and aterminal (delta) hydroxy group is a choline phosphate ester. An example of a di-fatty acid phosphatidylcholine is distearoylphosphatidylcholine, which is depicted below as formula VI:It is understood that other fatty acids can be used in place of stearic acid, which is representative only. For example, the fatty acid employed in said di-fatty acid phosphatidylcholine comprises a carboxyl group which forms an ester with the alpha and beta hydroxyl groups on the glycerol backbone, whereas the phosphatidylcholine forms on the a’ hydroxyl group (as shown above; a.k.a. sn-3). The fatty acids can be C9 to C27 alkyl chains.
[0140] In some aspects, the fatty acid employed can be any saturated or unsaturated long-chain fatty acid. In one aspect, the fatty acid is a saturated, naturally-occurring fatty acid of from 8 to 28 carbon atoms, and preferably from 15 to 22 carbon atoms. In some cases, the fatty acid is an unsaturated, naturally-occurring fatty acid of from 8 to 28 carbon atoms, and preferably from 15 to 22 carbon atoms. Table 1 below provides a list of some representative naturally occurring fatty acids (where the double bonds in all cases are in the cis conformation):TABLE 1
[0141] As used herein, the term “dry powder” refers to a composition comprising a population of fine particles prepared by the methods described herein. The dry powder is not suspended or dissolved in a propellant or other liquid. The dry powder composition cancontain up to about 4 weight percent water or up to about 6 weight percent water while otherwise retaining the aspects of an otherwise anhydrous material. Without being limited to any theory, the presence of a modest amount of water in the composition imparts stability to the composition and renders it resistant to water (e.g., substantially non-hygroscopic) at room temperature, thereby allowing for a long-term shelf-life.
[0142] The compositions of this disclosure comprise a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, and represent a paradigm shift in the treatment of PF. Rather than relying upon orally delivered drags with their attendant side effects, the present compositions are formulated for direct delivery to the deep pulmonary tract, with a major portion of the composition delivered into the lungs being deposited at the alveoli and adjacent tissue. In addition, the phosphodiesterase 3 / 4 (PDE3 / PDE4) inhibitory activity of the PDE3 / PDE4 inhibitor provides for anti-inflammatory activity and perhaps anti-fibrotic activity. The anti-inflammatory activity of PDE3 / PDE4 inhibitors provides an orthogonal treatment mechanism to the anti-fibrotic activity of an anti-fibrotic agent used in combination with the PDE3 / PDE4 inhibitor. These orthogonal activities is contemplated to synergistically interact with each other to enhance the overall benefits to the patient suffering from PF.
[0143] As the pathology of PF entails forming an oxygen-impermeable fibrotic scar over the alveoli, the progression of this disease continues until a sufficient portion of the alveoli are compromised and the patient dies either from the disease or from co-morbidities arising from the disease progression. To more effectively treat this disease, it is imperative that therapy at the site of the disease be integral to the process.
[0144] Ensifentrine, a PDE3 / PDE4 inhibitor, is currently administered via nebulization at a dose of 3 mg twice daily, and has been approved for the treatment of chronic obstructive pulmonary disease (COPD). The published literature teaches that, in COPD, ensifentrine reduces airway inflammation by enhancing bronchodilation and ciliary function in the bronchial epithelia, which are located in the middle to upper portions of the lung. See, e.g, Donahue, et al., J. Chron. Obs. Pul. Disease, 2023:18 1611-1622.
[0145] As per this disclosure, ensifentrine is now formulated for the treatment of PF and, as such, requires that the formulation deliver an efficacious amount of the dry powder composition containing a PDE3 / PDE4 inhibitor (e.g., ensifentrine or a pharmaceutically acceptable salt thereof) and an anti-fibrotic agent (e.g., nintedanib or a pharmaceutically acceptable salt thereof) to the deep pulmonary tract.
[0146] As described herein, a PDE3 / PDE4 inhibitor (e.g., ensifentrine or a pharmaceutically acceptable salt thereof) is now formulated for treating PF, which occurs in the deep pulmonary tract. As such, dry powder compositions suitable for inhalation delivery to treat PF necessarily must have an efficacious amount of the composition delivered to the deep pulmonary tract where the anti-fibrotic and anti-inflammatory activity of such compositions are able to treat the fibrosis and inflammation occurring adjacent to and at the alveoli. This is in contrast to the treatment of COPD where ensifentrine is formulated to treat airway inflammation by enhancing bronchodilation and ciliary function in the bronchial epithelia.
[0147] In one aspect, this disclosure provides for a dry powder formulation containing a PDE3 / PDE4 inhibitor (e.g., ensifentrine or a pharmaceutically acceptable salt thereof) and one or more anti-fibrotic agents (e.g., nintedanib or a pharmaceutically acceptable salt thereof), which powder has been manufactured to have a density and particle size which allows for such deposition of an efficacious amount of both agents into the deep pulmonary tract.
[0148] In one aspect, the compositions described herein comprise ensifentrine (or its pharmaceutically acceptable salt) and nintedanib (or its pharmaceutically acceptable salt). In some aspects, the composition further includes one or more of treprostinil, treprostinil palmitil, and pirfenidone, or a pharmaceutically acceptable salt thereof where applicable. Each of these components, either alone or in combination, is delivered in an efficacious amount directly at the site of disease progression, thereby reducing the amount of drugs required to achieve a therapeutically effective outcome for the individual patient. It is contemplated that delivery to the site of disease progression will benefit the patient in one or more of the following:• the amount of drug needed will be substantially lower compared to that required for oral delivery;• the resulting gastrointestinal tract side effects accompanying oral delivery of nintedanib or contemplated combinations with other therapeutic agents will be obviated or reduced to such an extent that the patient will stay on the therapy (e.g., improved medication compliance);• a portion of each of the two or more medicaments typically will be retained in the pulmonary tract, with a lower amount passing through the alveoli and entering the systemic circulation. The blood circulating portion of the two-drug combination (orthree-drug combination) will recirculate through the lungs but will also eventually be metabolized and eliminated without passing through the gastrointestinal tract;• there will be an increase in drug therapeutic efficacy and perhaps an increase in halflife in the lungs, especially if the free base of the drug is employed;• that the peak concentration achieved will be significantly higher at the site of disease progression than what can be achieved by oral delivery;• enhanced stability relative to a nebulizer formulation and nebulized delivery of the two drugs (or contemplated three or more drugs);• a decrease in inflammation as evidenced by the level of TGF-P production in the lung;• a decrease in cough frequency over time;• a decrease in coughing that occurs immediately during and after inhalation of the composition; and• the dry powder is substantially non-agglomerating in the delivery device, which can compromise delivery.
[0149] A desired therapeutic endpoint sought by use of the compositions described herein is the change of FVC, which the FDA requires 52 weeks vs comparator in Phase 3. TGF-P production in the lung, as an indication of decreased inflammation, can be measured to evaluate the effectiveness of ensifentrine. As formulated, the inventors contemplate that the combination of ensifentrine and an anti-fibrotic agent such as nintedanib, a non-specific tyrosine kinase inhibitor, will synergistically interact by two different mechanisms to reduce the overall inflammatory response and inhibit further development of additional fibrotic tissue. The inventors further contemplate that this synergy will lead to an otherwise unexpected result to one or more of the benefits recited above and / or slowing PF progression or arresting PF progression to a greater extent than either treatment alone.
[0150] Achieving a dry powder composition suitable for inhalation that comprises both a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, each of which treats PF by orthogonal mechanisms, necessitates that the dry powder composition must meet several features. For example, the dry powder composition requires a particle size and density that are consistent with inhalation delivery to ensure the delivery to the deep pulmonary tract while at the same time allowing for an efficacious amount of each drug to be delivered.
[0151] Complicating the delivery of efficacious amounts of each drug is the size of the ampoule (capsule) used in the delivery device. This limits both the amount of each drug (as a weight percent) found in the dry powder that can be included therein. In addition, thetotal lung dose (TLD) of a dry powder composition delivered by inhalation is a percentage of the nominal dose, meaning that a portion of the composition is lost during inhalation. Hence, delivery of an efficacious amount of each drug needs to account for drug loss during inhalation as well as ensuring that a sufficient amount of drug is delivered to the deep pulmonary tract so as to be efficacious.
[0152] As to the size and density, the particles in the dry powder composition have defined ranges which allow for including a sufficient amount of each drug into an ampoule. In addition, the particle size and density ranges also permit the composition to be emitted from the delivery device with sufficient velocity such that an efficacious amount of each drag reaches the deep pulmonary tract.
[0153] Still further, each drag, when combined, must be compatible with inhalation administration. As an example, nintedanib esylate is currently in clinical testing by Avalyn Pharma as a monotherapy for IPF using a nebulizer as the delivery vehicle. This disclosure addresses potential problems with this approach including:• The large difference in solubility between the free base and salt forms may lead to disproportionation of the salt to the free base and the acid used to manufacture the salt. Given that ethanesulfonic acid is a very strong acid (pKa ~ -1.7) and that the nominal dose of nintedanib in the lungs is expected to be > Img, there is concern that inhalation of unbuffered NES (as would be typical in a lactose blend) may cause a local irritant response and post-inhalation cough;• Given the high permeability of nintedanib esylate, increasing the solubility of the Class I iBCS drag may lead to suboptimal targeting within the lungs. Amorphous powders comprising nintedanib esylate may further increase solubility and speed dissolution, factors not in alignment with improving lung targeting.
[0154] In one aspect, this disclosure provides the free base form of either or both of the PDE3 / PDE4 inhibitor and the anti-fibrotic agent in order to provide for improved targeting and less frequent dosing. This is particularly important when it is known that the salt form of these drugs, if developed and administered, could disproportionate to the free base once deposited in the epithelial lining fluid. If so, there is reduced benefit to formulating the salt form. It may be possible to slow the disproportionation of the salt form by buffering the feedstock prior to spray-drying.
[0155] As a specific example, the esylate salt of nintedanib is commonly used as it improves solubility for oral delivery. However, as recited above, it is important to accountfor the effects of in situ solubilization rates and the subsequent residence time in the lungs after solubilization, which can lead to systemic absorption. For example, when the anti-fibrotic agent is nintedanib, the use of its free base form, which has significantly lower water solubility than the corresponding salt (e.g., esylate salt), may be more desirable. As above, solubilization decreases the lung residence time for this medicament. However, the very low water solubility of the free base delays solubilization when delivered directly to the deep pulmonary tract. Likewise, it will be true for any PDE3 / PDE4 inhibitor as well as any anti-fibrotic agent where the free base is sparsely water-soluble whereas the salt thereof is not. Hence, other anti-fibrotic agents or PDE3 / PDE4 inhibitors can also be considered for use as the free base form provided that there is a significant increase in solubility of the salt form as compared to the free base or free acid.
[0156] In addition to the above, the clinician also must determine whether the formulation can be predictably administered into a patient’s lungs in an efficacious amount, let alone achieving any one or more clinical benefits. The disclosed formulations are directed to density and particle sizes in the dry powder, together with the methods used for administration, which will overcome well-known obstacles in treating PF by directing a major portion of a medicament combination to the alveoli and adjacent tissue, thereby exemplifying the formulation and methods coupled with satisfying a long-felt unmet need for patients with PF.
[0157] In one aspect, when using a combination of nintedanib and ensifentrine, the use of the free base of nintedanib is contemplated to enhance retention in the deep pulmonary tract of the lung, such as at or adjacent to the alveoli, thereby delaying systemic uptake. The basis for asserting this is that the free base is less water-soluble than the corresponding salt (e.g., nintedanib esylate). Hence, dissolution of the nintedanib, a prerequisite to systemic uptake, is delayed, thereby retaining the free base in the deep pulmonary tract.A. Dry Powder Compositions of PDE 3 / 4 Inhibitors and one or more anti-fibrotic agents.
[0158] In one aspect, manufacturing methods are provided for forming a dry powder using ensifentrine as a representative PDE 3 / 4 inhibitor and nintedanib esylate as a representative anti-fibrotic agent. As above, the relative weight ratio of ensifentrine to nintedanib (both independent of the salt if administered as a pharmaceutically acceptable salt) is from about 0.125:1 to about 5:1 (about 1:8 to about 5:1). Specific embodiments for this ratio are set forth in Table 2 below:Table 2
[0159] Using Table 2 above and starting with 0.512 mg, 0.556 mg, 0.614 mg, 0.892 mg, 2.12 mg, or 3.0 mg of ensifentrine, the amount of nintedanib to be employed can be readily calculated based on these ratios. In some aspects, the amount of ensifentrine ranges from about 0.2 to about 2.5 mg per nominal dose.
[0160] Based on the above, the appropriate amounts of both ensifentrine and nintedanib were first established as follows:- the drug loadings were selected based on twice a day delivery (b.i.d.);both drugs and excipients used therewith would be delivered from a single capsule, assuming a 15 mg fill mass and a 50% delivery efficiency; and- the amount of each drug used is based on the weight of the free base.
[0161] Next, the hardware and process parameters to be used are fixed. Exemplary parameters are provided in Example 1 below. However, it is understood that the optimum parameters can vary with the particular drug combinations employed, the specific reagents and solvent(s) used, etc., and that such conditions can be determined by one skilled in the art by routine optimization procedures.Methodology
[0162] The formulation of dry powder compositions having the desired density and particle sizes is provided below.
[0163] The reagents used during synthesis are generally known, many of which are available from commercial vendors.
[0164] In general, the methods described herein provide a dry powder composition where the composition comprises a single medicament (e.g., a PDE3 / PDE4 inhibitor or an anti-fibrotic agent) or a combination of a PDE3 / PDE4 inhibitor and one or more anti-fibrotic agents. In one aspect, the dry powder compositions also include a di-fatty acid phosphatidylcholine, calcium chloride, water, and a dispersant or emulsifying agent. Such agents for use in dry powders are well known in the art. See, for example, Labiris, et al., Br. J. Clin. Pharmacol., 2003, 56(6): 600-612 and at column 40 of U. S. Patent No. 9,554,993, which are incorporated herein by reference in their entirety. These agents are conventional.
[0165] The methods for preparing the dry powder compositions include those set forth by Labiris, et al., supra, as well as Chaurasiya, et al., “Dry Powder for Pulmonary Delivery: A Comprehensive Review,” Pharmaceutics, 13(1): 31 (2020), both of which are incorporated herein by reference in their entireties. The ability to make a dry powder for pharmaceutical purposes is recited at length therein.
[0166] In order to achieve the particle size and density parameters for the dry powder compositions as described herein, the following general approach is provided. The Examples provided below set forth the specifics for the manufacturing methods. The manufacturing methods involve forming an emulsion comprising ultrapure water, a liquid suspension medium, and solids as described above and in the Examples. In some embodiments, the process steps include combining PC and water and homogenizing the combination using a high-shear mixer. This can be followed by the addition of calcium chloride (CaCL or hydrates thereof) while continuing to homogenize using a high-shear mixer. It is understood that magnesium chloride (MgCL) can be substituted for calcium chloride and is deemed to be an equivalent thereof.
[0167] Alternatively, calcium chloride (CaCL) can be added to PC and water. In the instance wherein water is present, the water must be heated in order to disperse the lipid. The degree of heating depends on the lipid used. The suspension medium is then added under high-shear mixing. The entire process is conducted at a temperature suitable for facilitating the formation of the stable nanoemulsion
[0168] In some embodiments, the relative amounts of ultrapure water and the liquid suspension medium range from about 8:1 to about 19:1 by weight. In some embodiments, the relative amounts of ultrapure water and the liquid suspension medium range from about 17:1 to about 19:1. In some embodiments, the amount of calcium chloride added is about 7.0 weight percent (wt%) or less or about 5.0 weight percent or less based on the total weight ofthe solids used where the amount of calcium chloride does not include any water of hydration. In some embodiments, the amount of anhydrous calcium chloride added is about 4.0 weight percent or less based on the total weight of the solids used. In some embodiments, the amount of anhydrous calcium chloride added is from about 2.0 weight percent to about 7.0 weight percent based on the total weight of the solids used. The total weight of the solids used ranges from about 1.0 to about 6.0 weight percent of the feedstock. CaCh, as an emulsion stabilizer, can increase the main transition temperature of PC in the dry state.Typically, CaCh can be added in a 1:2 mole ratio (mol Ca: mol PC) - (e.g., corresponding to 1:14.2 mass ratio)).
[0169] In some embodiments, the amount of phosphatidylcholine (PC) added is about 2 to about 30 weight percent based on the total weight of the dry powder. In some embodiments, the amount of PC can be about 30 to about 50 weight percent (wt%) based on the total weight. In some embodiments, the amount of di-fatty acid phosphatidylcholine added is about 35 to about 45 weight percent based on the total weight. In some embodiments, the amount of di-fatty acid phosphatidylcholine added is about 35 weight percent, about 40 weight percent, about 45 weight percent, about 50 weight percent, about 60 weight percent, about 70 weight percent, about 80 weight percent, or about 85 percent based on the total weight.
[0170] The ultra-pure water is characterized as follows in Table 3:Table 3The water is further passed through a 0.20-micron filter to remove microbial contamination.
[0171] The drug(s) and emulsion are combined and can be processed in a high-pressure homogenizer to facilitate the formation of a stable emulsion-based feedstock. Once a stable feedstock is formed, it can be spray-dried to form a dry powder. In some aspects, the resulting dry powder can have an ultra-low bulk density (approximately from about 0.03 g / cc to about 0.15 g / cc or from about 0.04 g / cc to about 0.11 g / cc). The resulting dry powder hasa uniform concentration of actives dispersed throughout and a uniform concentration of drug active or actives.
[0172] Spray drying is a particle engineering technique that can be used for the compositions described herein to manufacture respirable pharmaceutical powders. The technique has been demonstrated to work with both small molecules and biological actives, including proteins. For example, actives and excipients can be co-emulsified in a volatile solvent and then atomized into droplets that are sprayed into a drying chamber. Heated drying gas rapidly removes the solvent, resulting in a dried powder that is collected via cyclone or baghouse. The outlet temperature used during powder manufacture must be maintained such that the powder formed is not compromised. As such, process conditions including the inlet temperature, the liquid feed rate, the drying gas flow rate, and other factors are necessarily controlled to provide for the required outlet temperature.Alternative Methodology
[0173] The spray-drying manufacture of an inhalation formulation with more than one active compound can be challenging. However, two or more active pharmaceutical ingredients (APIs) can be combined into a single feedstock and spray-dried, provided that chemical compatibility is met as are the requirements for maximizing each ingredient’s physicochemical stability. The examples below evidence that the APIs described herein are compatible. However, in the event that compatibility and stability of the multiple APIs are not met, then each active API could be formulated and spray-dried separately, and then the two spray -dried compositions can be blended together at the appropriate ratios to provide the requisite amount of these APIs in the combined composition. This approach introduces additional processing steps and potential difficulties in content uniformity and is particularly challenging for inhalation powders, which have very poor flow and are often hygroscopic. See, e.g., K. B. Shephard et al,, “Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations,” Pharmaceutics 14(6): 1130 (2022) and R. Vehring, “Pharmaceutical Particle Engineering via Spray Drying,” Pharm. Res. 25(5): 999-1022 (2007). Nevertheless, these challenges can be resolved by, for example, a biologically compatible tracer molecule that is added to a small portion of one of the dry powder compositions during manufacture. When this dry powder is mixed with another dry powder, the uniformity of the tracer molecule can be checked by taking a number of samples and assessing the signal generated.If a substantially uniform signal is found in various samples, a uniform composition is confirmed.
[0174] Nevertheless, it is contemplated that a dry powder composition prepared by mixing APIs prior to the manufacturing process described herein will provide for greater uniformity than generating a dry powder of each and then mixing.
[0175] In embodiments of the disclosure, a dry powder for each API that will be combined is either dissolved or suspended in an aqueous solvent (e.g., a generally volatile solvent that is preferably pharmaceutically acceptable for use in the manufacture of pharmaceuticals, even when the solvent is evaporated from the final product). In another embodiment, the drug is maintained in crystalline form and is not dissolved.
[0176] In some embodiments, a single dosage form or a portion of a single dosage is filled into a capsule or blister for delivery by a conventional inhaler device.
[0177] It is also contemplated that the addition of treprostinil palmitil or treprostinil to an ensifentrine-nintedanib combination, drug synergy may be further enhanced because treprostinil palmitil and treprostinil inhibit smooth muscle growth. In PF, pulmonary muscle growth creates a tissue foundation for the collagen deposits to take hold. Clinically, it is desirable if at least two times as much drug that can be absorbed by a diseased lung cell is achieved via pulmonary administration of the drug than the amount of drug that is absorbed by a diseased lung cell if delivered orally, even assuming the cellular half-life of the drugs administered orally and via inhalation are equivalent; currently such cellular uptake is not occurring in patients receiving oral administration of each agent in the form of a monotherapy.
[0178] Such clinical synergies are not available with the combination of a PDE3 / PDE4 inhibitor or with a further combination such as with a PDE3 / PDE4 - nintedanib - treprostinil palmitil or treprostinil if nintedanib is administered orally given its pharmacokinetics and adverse effects in patients, causing patients to stop therapy. Known adverse effects encountered by nintedanib oral monotherapy include: nausea, a rash, stomach pain, an upper respiratory tract infection, diarrhea, fatigue, a headache, indigestion, dizziness, decreased patient appetite or loss of appetite, gastroesophageal reflux disease (GERD), sinusitis, sleeplessness, weight loss, and joint pain.
[0179] In addition, it is contemplated that a combination of an effective amount of each of a PDE3 / PDE4 inhibitor (e.g., ensifentrine) and an anti-fibrotic agent (e.g., nintedanib) in a form suitable for inhalation is more efficient and effective than serialdelivery of an inhaled formulation comprising only a PDE3 / PDE4 inhibitor followed by or preceded by delivery of an inhaled formulation comprising only an anti-fibrotic agent.
[0180] Without being limited to any theory, it is contemplated that the homogenous composition comprising a PDE3 / PDE4 inhibitor (e.g., ensifentrine) and an anti-fibrotic agent (e.g., nintedanib) prepared in a single spray-drying procedure as described herein results in the simultaneous and direct targeting of the interstitial region of the alveolar membrane. In contrast, separate administration introduces uncertainty of delivery to the intended site of action and the amount so delivered. Without being limited to any theory, serial administration may reduce the amount of the second drug delivered relative to the first, both as to the total amount of drug delivered and delivery into the deep pulmonary tract.
[0181] It is recognized that nintedanib esylate is conventionally used in oral formulations due to its significantly different solubility as compared to the free base and is included for use herein for forming a dry powder. However, for patients whose PF includes coughing as a serious component or a potential serious component of the disease, the esylate salt may be contraindicated. Without being limited to any theory, this is due to the large difference in solubility between the free base and salt forms. This difference leads to disproportionation of the salt to the free base and the acid used to manufacture the salt. Given that ethanesulfonic acid is a very strong acid (pKa ~ -1.7) and that the nominal dose of nintedanib in the lungs is expected to be > 1 mg, inhalation of unbuffered nintedanib esylate may cause a local irritant response and post-inhalation cough.
[0182] Still further, given the high permeability of nintedanib esylate, increasing the solubility of the Class I iBCS drug may lead to suboptimal targeting within the lungs.Amorphous powders comprising nintedanib esylate may further increase solubility and speed dissolution, factors not in alignment with improving targeting to the deep pulmonary tract. However, the use of the free base form of nintedanib is contemplated to provide improved targeting and less frequent dosing. Accordingly, in one embodiment, there is provided a dry powder composition comprising the free base of nintedanib. The density and particle size of this powder is as provided above.
[0183] In addition, given that the salt form could disproportionate to the free base once deposited in epithelial lining fluid, there is risk in formulating the salt form. It may be possible to slow the disproportionation of the salt form by buffering the feedstock prior to spray-drying. In one aspect, provided is a dry powder composition comprising a salt of nintedanib and a buffer.Delivery Devices
[0184] The dry powder compositions are delivered into the deep pulmonary tract via conventional devices such as an RS-01 Amcor inhaler, an Emphasys CDAHaler®, a Turbohaler® inhaler, an Accuhaler® inhaler, or an Ellipta® device. A Symbicort Turbohaler® (AstraZeneca, UK) is a plastic device employing a breakable capsule that, once broken, is breath-activated. Following the directions provided, as the patient inhales, the dry powder is released and delivered into the patient’s lungs.
[0185] Accuhaler® (Glaxo Smith Kline, UK) is another example of a capsule-based inhaler similar to the Turbohaler®. Other inhalers for use with the dry powder compositions are provided in, for example, U. S. Patent Nos. 11,517,548; 11,690,819; and 11,752,100, supra.
[0186] Generally, inhaling dry powder may induce coughing. When administered by oral inhalation, it is contemplated that the dry powder composition disclosed herein may induce less or no substantive coughing. This outcome would represent a marked improvement for therapeutic agents administered by oral inhalation.Methods
[0187] The compositions and methods described herein are useful in treating PF. Such methods comprise administering via pulmonary inhalation an effective amount of a composition described herein. Specifically, the methods comprises administering a dry powder composition suitable for inhalation therapy, which composition comprises a PDE3 / PDE4 inhibitor and / or an anti-fibrotic agent. In some aspects, the PDE3 / PDE4 inhibitor is ensifentrine. In some aspects, the PDE3 / PDE4 inhibitor is HSK39004 / AN01. In some aspects, the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701. In some aspects, the PDE3 / PDE4 inhibitor is TQC3721. In some aspects, the anti -fibrotic agent is a nintedanib salt (e.g., nintedanib esylate). In some aspects, the anti-fibrotic agent is the free base of nintedanib. In some aspects, the anti-fibrotic agent is treprostinil. In some aspects, the anti-fibrotic agent is treprostinil palmitil. In some aspects, the anti-fibrotic agent is treprostinil sodium. In some aspects, the anti-fibrotic agent is pirfenidone. In some aspects, the anti-fibrotic agent is deupirfenidone. In some aspects, the anti-fibrotic agent is nerandomilast. In some aspects, the anti-fibrotic agent is vismodegib. In some aspects, the anti-fibrotic agent is taladegib.
[0188] In some aspects, the attending clinician determines that the patient is best treated by a single active agent. In some aspects, the attending clinician determines that thepatient is best treated by a combination of two or more than two active agents (e.g., ensifentrine and nintedanib). It is contemplated that combinations using a PDE3 / PDE4 inhibitor and an anti-fibrotic agent will benefit the patient, because both drugs have at least one unique mechanism of action as compared to the other drug. Moreover, it is contemplated that such unique action by each drug may be synergistic.
[0189] In some aspects, there is provided a method for treating idiopathic pulmonary fibrosis in a patient, which method comprises:a) confirming that the patient is currently diagnosed with either Stage 1 or Stage 2 idiopathic pulmonary fibrosis;b) administering directly to the lungs of said patient a composition comprising a dry powder composition which itself comprises a population of particles, which particles comprise:i) an effective amount of a pharmaceutical combination of a PDE3 / PDE4 inhibitor or a pharmaceutically acceptable salt thereof, and an anti-fibrotic agent; ii) a phosphatidylcholine compound in an amount sufficient to impart stability to said particles; andiii) an effective amount of calcium chloride;wherein said powder composition comprises particles having a median particle size (diameter along the longest axis or average geometric diameter) of from about 0.5 to about 15 pm, such as about 5.0 about 15 pm; and a bulk density of from about 0.03 g / cc to about 0.3 g / cc, such as about 0.04 g / cc to about 0.11 g / cc. For an average geometric diameter, one averages Feret’s horizontal and vertical diameters. If the measurement is carried out on a large number of randomly oriented particles, the reported geometrical diameter is the orientation- averaged Feret’s diameter. See Vehring “Pharmaceutical Particle Engineering via Spray Drying,” Pham. Res. 25(5): 999-1022 (2007).
[0190] In some aspects, patients with IPF and treated as per the methods above, will exhibit a reduction in the rate of disease progression as compared to patients not undergoing said pharmacotherapy. In some embodiments, said reduction in the rate of progression is at least 10%, at least 20%, at least 30%, at least 50%, or at least 75% less than that rate of progression of said disease for patients not treated with the methods described herein.
[0191] In some embodiments, this disclosure provides for a method to qualify a patient with IPF for pharmacotherapy treatment of idiopathic pulmonary fibrosis with a composition as described herein, which method comprises:a) selecting a patient diagnosed with idiopathic pulmonary fibrosis;b) evaluating said patient to determine the stage of the disease for that patient; c) disqualifying patients from said pharmacotherapy who are currently diagnosed as being in either stage 3 or stage 4 for oxygen requirements of the disease; d) initiating pharmacotherapy for patients who are determined to be at the incipient stage of the disease (stage 1 of oxygen requirements) or at a moderate stage of the disease (stage 2 of oxygen requirements);e) monitoring said patients to determine the extent of the progression of said disease after initiating pharmacotherapy andf) optionally removing said patients from pharmacotherapy for whom the attending clinician determines that pharmacotherapy is no longer effective.
[0192] In some aspects, this disclosure provides for a method for treating qualified patients diagnosed with pulmonary fibrosis, which method comprises:a) confinning that said patient has been qualified for said pharmacotherapy with a composition as described herein;b) initiating pharmacotherapy for said patient;c) maintaining said pharmacotherapy until the attending clinician determines that the disease progression has evolved such that there is no longer a benefit to the patient andd) terminating said pharmacotherapy.
[0193] In some aspects, the attending clinician can determine the degree of progression of the disease based on the PF scale set forth herein. In some embodiments, the attending clinician can ascertain the degree of progression of the disease based on the increased rate of oxygen usage.
[0194] Further contemplated are dry powder compositions of the disclosure comprising ensifentrine and / or nintedanib and any other therapeutic agents targeting PF or other pulmonary diseases, including but not limited to pulmonary arterial hypertension (PAH), and pulmonary hypertension in interstitial lung disease (PH-ILD), and that can be administered by oral inhalation.
[0195] Accordingly, dry powder compositions of the disclosure comprising ensifentrine and / or nintedanib and treprostinil palmitil are contemplated. Treprostinil is currently in development for IPF and PPF. Treprostinil palmitil inhalation powder (TPIP) is a long-acting prodrug of treprostinil and a new chemical entity (NCE) that enables reduceddaily dosing frequency compared to treprostinil, which requires 4 doses daily. Exemplary doses of TPIP are 80 to 640 microgram (mcg) doses administered once a day.
[0196] It is further contemplated that compositions described herein may comprise any additional therapeutic useful methods for treating PF or other pulmonary diseases that can be administered by oral inhalation of the dry powder composition of the disclosure. Such methods comprise delivering via pulmonary inhalation an effective amount of the dry powder compositions described herein. The methods can employ ensifentrine and / or nintedanib, and optionally treprostinil palmitil, treprostinil, and / or pirfenidone. Other contemplated therapeutics include admilparant, bexotegrast, buloxibutid, nerandomilast, taladegib, or vismodegib. In some contemplated embodiments, the methods can employ ensifentrine, nintedanib, and treprostinil palmitil. In some contemplated embodiments, the methods can employ ensifentrine and treprostinil palmitil. In some contemplated embodiments, the methods can employ nintedanib and treprostinil palmitil. In some contemplated embodiments, the methods can employ ensifentrine. In some contemplated embodiments, the methods can employ ensifentrine and / or treprostinil palmitil. In some contemplated embodiments, a dry powder composition comprising both ensifentrine and nintedanib and treprostinil palmitil is used to treat PF or other pulmonary diseases in a patient. It is contemplated that when so used, the combination of the three or four drugs will benefit the patient because the drugs have unique mechanisms of action relative to the other drugs. It is contemplated that such unique action by each drug may be synergistic.EXAMPLES
[0197] In addition to the definitions above, the following terms are used in the examples below and in the specification and have the following meanings. Terms not defined have their scientifically accepted meanings. In addition, all temperatures reported are ± 15% of the stated value and given in degrees Celsius unless stated otherwiseDefinitions
[0198] In the Examples below, the following reagents were used:Reagents:- Ensifentrine was obtained from INKE (Barcelona, Spain). This batch of Ensifentrine is predominantly crystalline, as determined by X-Ray powder diffraction.- NES was obtained from Cipla (Mumbai, India) and was also predominantly crystalline.- Nintedanib free base was prepared by deliberate disproportionation of crystalline NES.Excipients:Calcium chloride dihydrate was obtained from Spectrum.- HSPC was obtained from Lipoid GmbH (Batch 2240846-01 / 019).- Leucine (Emprove Expert grade) was obtained from Sigma-Aldrich.Process Aids.- The spray-dried drug product also contains residual water and PFOB.USP Perflubron was obtained from Exfluor Research Corp. (Round Rock, TX).- Water was manufactured on site at Flurry Powders (San Leandro, CA) using a RO / DI system (resistivity > 18MΩ).Example 1 - Formation of Dry Powder Compositions with a Single Active Agent
[0199] This example evaluated three different dry powder compositions using a single active agent. The first composition used ensifentrine as the active agent; the second composition used nintedanib esylate as the active agent; and the third composition used nintedanib free base as the active agent. Each of these compositions used the same format but for the active agent used. The compositions were prepared using a theoretical amount of reagents as per Tables 4 to 6 provided below.Table 4. Theoretical compositions of anhydrous formulations - Composition AComponent Function Amount (%w / w)Ensifentrine Drug substance 8.2HSPC Shell former 85.7Calcium chloride Modifies lipid phase behavior 6.1• Ca / PC: 0.5 mol / molTable 5 Theoretical compositions of anhydrous formulations - Composition BComponent Function Amount (%w / w)Nintedanib esylate Drug substance 25.7HSPC Shell former 69.4Calcium chloride Modifies lipid phase behavior 4.9• Ca / PC: 0.5 mol / molTable 6 Theoretical compositions of anhydrous formulations - Composition CComponent Function Amount (%w / w)Nintedanib base Drug substance 14.0HSPC Shell former 2.34Calcium chloride Modifies lipid phase behavior 5.52• Ca / PC: 0.5 mol / mol
[0200] In each case, the lipids and calcium chloride were first dispersed in hot water with a high-shear mixer (UltraTurrax) to form multilamellar vesicles (MLVs). The aqueous phase was retained above the gel-to-liquid-crystal phase transition temperature of the lipids (Tm) to facilitate MLV formation. The MLV dispersion was cooled (< 30°C), and PFOB was added dropwise along the shaft of the high-shear mixer (5000-7000 RPM) to form coarse PFOB -in-water emulsion droplets stabilized by a monolayer of the lipids and serve as pore formers to create a porous coating of lipids on the crystalline drug particles. The coarseemulsion was then homogenized to form nanoemulsion droplets. Homogenization was conducted for about 15 minutes at increasing pressures to a maximum of 15000 psi. Next, the drug substance was added under high-shear mixing to the nanoemulsion. The complex dispersion comprising suspended drug and nanoemulsion droplets was then homogenized for about 15 minutes at increasing pressures to a maximum of 15000 psi, ending with a single, discrete pass at 15000 psi. The homogenization process wet mills drug particles to a suitable size for pulmonary delivery. The final feedstock composition had a solids content of 1.5% w / w, a PFOB content of 10% v / v, and a theoretical batch size of 3.5 g (except for batch made with nintedanib free base). This was done to conserve the amount of available nintedanib free base.Production of Dry Powders by Spray-drying
[0201] The liquid feed was supplied to the atomizer and into the spray dryer with a peristaltic pump. The atomizer was operated at a gas flow of 1500 L / h and an inlet temperature of 125 ± 5 °C. The liquid feed rate was 4.4 g / min, resulting in a dryer outlet temperature of 62 ± 3 °C. The drying gas flow was about 27 m3 / h.
[0202] In suspension-based feeds, each atomized droplet (mass median diameter ~ 10 pm) contains dispersed drug crystals and approximately 1000 sub-micron emulsion droplets (Weers, et al., AAPS PharmSci Tech., 2019; doi;10.1208 / sl2249-018-1280-0). During the initial moments of the drying process, the more volatile aqueous phase begins to evaporate. The rapidly receding atomized droplet interface drives enrichment of the slowly diffusing drug and emulsion particles at the interface. This leads to the formation of a void space in the center of the drying droplet. As the drying process continues, the less volatile oil phase in the emulsion droplets evaporates, resulting in the formation of hollow pores in their place.Overall, the resulting hollow spray -dried composite particles contain drug crystals embedded in an interfacial layer of a porous lipid matrix.Example 2 - Formation of Dry Powder Compositions Containing Two Active Agents
[0203] This example evaluates dry powder compositions of four (4) fixed-dose combinations of ensifentrine with three compositions using nintedanib free base with or without PFOB and one with nintendanib esylate in order to screen the aerosol performance and accelerated chemical stability of these compositions.
[0204] These compositions were made consistent with Example 1 except that a second active compound (nintedanib esylate or free base) was included using an ensifentrine to nintedanib (E: N) ratio of 0.614 mg E and 1.6 mg of N. The absolute drug loadings in these formulations were selected such that the doses of both drugs would be delivered from a single capsule, assuming a 15 mg fill mass and a 50% delivery efficiency.
[0205] As the above, this example employs four fixed-dose combinations of ensifentrine and nintedanib as follows:• Composition D utilizes the suspension format for both ensifentrine and nintedanib free base with 10% v / v PFOB;• Composition E utilizes the same composition as Composition D, but without the PFOB droplets.• Composition F utilizes ensifentrine and nintedanib free base from a suspension feedstock. Leucine replaces HSPC as the primary shell-forming excipient, although a small amount of HSPC is included as a surfactant to improve suspension stability for the APIs in the liquid feedstock. Pore-forming agent was not included in this composition.• Composition G utilizes the suspension format for ensifentrine and the solution format for nintedanib esylate with 10% v / v PFOB. At a feedstock solids content of 3% w / w and a loading of 25.7% w / w nintedanib esylate, the nintedanib esylate concentration will be about 7.7 mg / mL, below its reported solubility of 20 mg / mL. Given that nintedanib esylate will dissolve in the feedstock, it will be present as an amorphous solid in the powder. Formulation as an amorphous solid carries increased risk of physical and chemical stability issues, as well as negative implications for device performance and drug delivery at high relative humidity.
[0206] The compositions of the four spray-dried powders are detailed in Table 7, while Table 8 summarizes the parameters relevant to powder production at the PSD-1 scale. The spray dryer was cleaned prior to this manufacturing. Although the dryer was not cleaned between lots, care was taken to minimize the possibility of powder carryover from one lot to another. This includes spray drying the powders in a specific order and procedural steps between runs, e.g., use of a dummy collector, mechanical pulsing (cycling the isolation valve with dummy collector installed) to remove any powder from the lower end geometry, etc.Table 7. Compositions of spray-dried powders with fixed dose combinations of ensifentrine and nintedanibRationale - Composition D - “Base” fixed dose combination. Use the free base as a solid-state form.Rationale - Composition E - “Base” fixed dose combination. Use the free base as a solid-state form. No PFOBRationale - Composition F -fixed dose combination. Use the free base as a solid-state form. Small amount of HSPC as a wetting agent.Rationale - Composition G - 'Base' fixed dose combination. Use esylate as a solid-state form.Table 8. Hardware and Process Parameters Utilized for Example 2 (Fixed Dose Combinations of Nintedanib and Ensifentrine* Adjusted to maintain outlet temperatureExample 3 - Methods for evaluating the compositionsAPI Content
[0207] Ensifentrine and Nintedanib: Ensifentrine and nintedanib content in bulk spray -dried powder composition and samples were determined using reverse-phase high-performance liquid chromatography (RP-HPLC). Detection was performed at 390 nm for nintedanib and 350 nm for ensifentrine.
[0208] Samples were analyzed using an Agilent 1260 Infinity II HPLC system (Wilmington, DE, USA). Chromatographic separation was achieved on a Phenomenex Luna C18 column (150 x 3 mm, 3 pm) using a gradient elution method, with mobile phase A consisting of 0.1% TFA in water and mobile phase B consisting of 0.1% TFA in acetonitrile.
[0209] Ensifentrine and nintedanib were quantified using a single-point calibration approach, with the reference standard prepared as a neat drug solution in 0.1% TFA in a 70:30 (v / v) water: acetonitrile diluent.Aerosol characterization
[0210] Aerodynamic particle size distributions (aPSD) were determined using a RS01 dry powder inhaler (Mod. 7 Ultra High Resistance 2 Model), USP induction port (IP), and Next Generation Impactor (NGI) and conform to USP <601 > and Ph. Eur. 2.9.18. The flow control apparatus is adjusted to operate at a 4 kPa pressure drop (Q = 46.7 L / min) and for a total volume of 4 L through the inhaler.
[0211] Approximately 6.5 mg ± 0.5 mg was hand filled into size #3, clear, inhalationgrade HPMC capsules (Qualicaps: Quali-V-I). The aerosol powder emitted from the inhaler is drawn through the USP IP and is sized in the NGI following Analytical method: Next Generation Impactor (NGI) - Gravimetric APSD, ref. 0002-AM-vl.).Tapped Density and Bulk Density
[0212] Tapped density ptapped)wasdetermined using a cylindrical cavity of known volume (0.593 cm3) following Test method: Measuring UC Bulk and Tapped Density, ref.0070-TM. Powder was filled into this sample holder using a microspatula. The sample cell was then gently tapped on a countertop. As the sample volume decreased, more powder was added to the cell. The tapping and addition of powder steps were repeated until the cavity was filled, and the powder bed no longer consolidated with further tapping. The tappeddensity is defined as the mass of the tapped bed of powder divided by the volume of the cavity.
[0213] The bulk density (Pbuik) represents the density for the powder that is loaded into the sample holder to the requisite volume without tapping.
[0214] The Carr index, C, provides an indication of powder compressibility. It is given by:As Carr’s index increases, the flowability of the powder is thought to decrease. Values <10% are thought to be indicative of excellent, free-flowing powders, 11-15% good, free-flowing powders, 16-20% fair powder flow, 21-25% passable powder flow, 26-31% poor flow cohesive, 32-37% very poor flow, very cohesive, and >38% no powder flow properties.Primary Particle Size Distribution by Laser Diffraction
[0215] Primary particle size distributions of spray-dried powders were determined using laser diffraction with a Malvern Mastersizer 3000 equipped with an AeroS dispersion cell (Malvern, UK) operated at 4 bar. A Mie scattering model was employed to determine particle size distributions.Water Content
[0216] Water content was determined by coulometric Karl Fischer titration using a Metrohm Karl Fischer titration system consisting of a Metrohm 874 KF Oven coupled with a Metrohm 852 KF Titrando, equipped with appropriate burettes and electrodes. The sample was heated in the KF oven, and the released water was transferred to the titration cell by a dry carrier gas for coulometric determination. The analysis was conducted in accordance with the laboratory’s internal procedure for water determination by Karl Fischer oven vaporization: Operation and Maintenance of the Metrohm 852 KF Titrando with 874 KF Oven.X-ray powder diffraction (XRPD)
[0217] X-ray powder diffraction patterns of selected powders were measured with a Rigaku Miniflex Model 600 diffraction system equipped with a D / Tex solid state ‘strip’ detector (Rigaku, Tokyo, Japan). Each sample was prepared by packing bulk powder into a sample holder with a zero-background silicon insert (23 mm diameter x 1 mm depth, part #1018376). Samples were scanned from 3 to 45°20 with a step size of 0.02°2θ and a scan rate of 0.5°2θ / min. This instrument uses a Cu radiation source with a wavelength of 1.54 A,operated at 40 kV and 15 mA. During measurement, the sample is rotated in its plane at 80 RPM.Differential Scanning Calorimetry (no modulation)
[0218] The DSC thermogram of a given sample was measured using a TA Instruments Model Q2000 differential scanning calorimeter equipped with a Refrigerated Cooling System (New Castle, Delaware). The sample cell was purged with dry nitrogen at a flow rate of 50 cm3 / min; the Refrigerated Control System (RCS) used nitrogen at a flow rate of 110 cm3 / minute. Tzero aluminum pans that contained between about 2 and 8 mg of powder were hermetically sealed using a sample encapsulation press.
[0219] In a DSC experiment, the sample was first cooled to -90°C, equilibrated for about 5 minutes, and then heated at 5°C / minute to a temperature as high as 320°C (i.e., depending on the thermal event of interest). The heating rate was not modulated. Each reported Tmcorresponds to the extrapolated onset of the transition.Example 4 - Assessing E and N Content in the Sprayed Dry Samples of Example 2
[0220] This example assesses the ensifentrine and nintedanib content in the spray-dried compositions of Example 2. Specifically, ensifentrine and nintedanib content was determined by RP-HPLC. The results are shown in Table 10 below. For each spray -dried powder, the recovery is calculated as the ratio between the measured drag content and the theoretical content calculated based upon masses of drug and excipients used in feedstock preparation. The ensifentrine powder (Composition A) was enriched in ensifentrine. This has been observed in other suspension-based formulations and is an artifact of the cyclone used in Example 2 for composition A. Specifically, there is a population of particles that contain no drag (‘blank’ particles). This is a statistical probability based upon the relative size distributions of the atomized droplets and the suspended micronized drag. In this case, these blank particles can be aerodynamically small and not collected by the cyclone. This results in enrichment of the ensifentrine in the remaining particles. However, this effect will happen, but to a lesser extent, on a larger scale spray-dryer, where gas velocities and cyclone fine particle collection efficiencies are greater (in part, also due to cyclone design).
[0221] As per Table 10 below, the recoveries of drag from Compositions B and C are within expectations for batches of this size. For a 3.5 g batch at 1.5% w / w solids, the mass of feedstock is only about 220 mL. Note that the results for Composition C were subdivided intothree collection intervals (1, 2, 3) due to loss of liquid feed during spray -drying, resulting in a rise in the outlet temperature.Table 10*Calculated based upon masses of drug and excipients used in feedstock preparation, expressed on a neutral compound basis.Example 5 - Assessing Primary Particle Size Distributions of the Dry Powders of Example 1
[0222] This example assesses the primary particle size distributions (PPSD) which were obtained by laser diffraction for the nintedanib and ensifentrine powders and are presented in Table 11 below.Table 11. Primary particle size distributions of formulations of ensifentrine and nintedanibThe size distribution range (D) that captures “x” percent of the volume (or mass) particles (“D-x”) is shown in Table 11 for D-50 and D-90 values for a suspension of particles for CNES were 1.79 pm and 4.18 pm, respectively. In contrast, the PPSDs in suspension-based formulations depend on the size of the crystalline drug particles embedded in the lipid matrix. For the suspension-based formulations of nintedanib base, the D-50 values ranged from 2.22 pm to 2.75 pm and the D-90 values from 5.13 pm to 6.50 pm. The D-50 and D-90 values for the suspension formulation of ensifentrine were 2.62 pm and 6.19 pm, respectively. Overall, the values presented are typical of spray-dried particles produced from emulsion-based feedstocks.Example 6 - Assessing Bulk Densities of the Dry Powders of Example 1
[0223] The bulk and tapped densities as well as measures of bulk powder flow (Carr's Index and Hausner Ratio) are shown in Table 12 below. The density values are within the range typical of dry powder compositions. The densest powder, Composition C, was a suspension-based formulation prepared with nintedanib free base. Although such ‘lipid-coated crystal’ formulations tend to be denser than solution-based powders, the other suspension-based formulation, Composition A, was the least dense of the three powders (albeit having about a threefold lower drug loading than Composition C).
[0224] Carr’s index and Hausner Ratio are measures of compressibility and serve as indicators of powder flowability, with larger values being indicative of poorer powder flow. For Carr’s index, values <10% are thought to be indicative of excellent, free flowing powders, 11-15% good, free flowing powders, 16-20% fair powder flow, 21-25% passable powder flow, 26-31% poor flow cohesive, 32-37% very poor flow, very cohesive, and >38% no powder flow properties. Per this definition, the powders range from ‘good’ (PB251203-3) to ‘poor’ (PB251203-2) to ‘no powder flow’ (PB251203-1). Note that these qualitative measures do not consider the forces used to encourage powder flow, such as the use of ultrasonic transducers during powder filling or the design features of the DPI that drive powder fluidization and dispersion during dose administration. The utility in these measures of powder flow is in comparing different variants of a given formulation type (e.g., the effect of PFOB concentration, process parameters, solids content, etc.). The densities and flow properties are provided in Table 12 below:Table 12. Densities and powder flow properties of formulations of ensifentrine and nintedanibExample 7 - X-Ray Powder Diffraction Patterns for the Dry Powders of Example 1
[0225] The physical form of the drug in the spray-dried formulations was determined by X-Ray Powder Diffraction (XRPD). An overlay of the X-ray powder patterns of spray-dried Compositions A, B, and C powders is shown in Figure 2. When comparing these powder patterns, it is clear that Composition B is qualitatively the least crystalline, as given by the lower number and intensity of drug-related diffraction peaks. This is due to the dissolution of NES in the feedstock, resulting in primarily amorphous NES in this formulation. The following figures review the XRPD results of each formulation with respect to the relevant crystalline reference powder patterns.
[0226] Figure 3 shows an overlay of the X-ray powder patterns of spray -dried ensifentrine powder Composition A and the ensifentrine drug substance. The major diffraction peaks of ensifentrine are observed in the spray-dried powder, indicating that the spray -dried powder contains crystalline ensifentrine. This would be expected for a powder spray dried from a feedstock in which ensifentrine was suspended as a crystal. The peaks at 5.1°20 and 21.3°20 are attributed to gel-phase phospholipid.
[0227] Figure 4 shows an overlay of the X-ray powder patterns of spray -dried NES Composition B, and references the XRPD patterns of NES and nintedanib free base. The peaks at 5.1°20 and 21.3°20 are attributed to gel-phase phospholipid. The other peaks in the pattern of Composition B are weak, indicating poor crystallinity of nintedanib in this powder. This would be expected for a formulation with NES, which would have a high dissolved fraction in the spray -dried feedstock. Given the possibility of disproportionation of NES in aqueous media (resulting in nintedanib base and ethanesulfonic acid), it is of interest to assess the solid form of the weak crystalline peaks in the X-ray powder pattern of powder Composition B. In an attempt to identify the weak peaks, a 20 x enlargement of the powder patterns is shown in Figure 5.
[0228] Figure 5 expands the results of Figure 420-fold. In Figure 5, the ‘peaks’ at 7.8 and 17.4°20 have been annotated with dashed lines - both can be attributed to NES. The powder pattern shows an inflection at 6.6°20 that could indicate nintedanib free base but such is not definitive.
[0229] Figure 6 shows an overlay of the X-ray powder pattern of spray-dried nintedanib free base Composition C and a reference pattern of nintedanib free base. The major diffraction peaks of nintedanib free base are observed in the spray-dried powder (as annotated by the dashed lines), indicating that the spray -dried powder contains crystallinenintedanib free base. This would be expected for a powder spray-dried from a feedstock in which nintedanib free base was suspended as a crystal. The peaks at 5. O°20 and 21.3°29 are attributed to gel-phase phospholipid. Note that the small peak at 7.6°20 has yet to be identified.Example 8 - Assessing E and N Content in Compositions D, E, F and G
[0230] The contents of ensifentrine and nintedanib in the spray-dried formulations ofExample 2 are detailed in Table 13. In most cases, some enrichment in drug content is observed as was described above in Example 4.Table 13 Drug content in nintedanib base API and spray-dried batches of a fixed dose combination of nintedanib and ensifentrine.Example 9 - Assessing Water Content
[0231] The water content of Compositions D, E, F, and G are typical of spray-dried dry powders. The water content of the leucine-based powder is markedly lower (0.78% w / w) due to the crystalline nature of leucine and its inherently lower hygroscopicity relative to the phospholipid matrix. This likely provides an advantage with respect to the environmental robustness of aerosol performance. These results are provided in Table 14.Table 14 Water Content of Spray-Dried Ensifentrine / Nintedanib PowdersExample 10- Assessing Physical Properties - Density and Flow Properties
[0232] The density and flow properties of Compositions D, E, F, and G produced in Example 2, along with bulk and tapped densities and powder flow properties were evaluated. Each of the spray-dried powders had approximately the same powder mass(yield), so the difference in the volume of powder within the containers reflects differences in bulk density. The results are provided in Table 15.Table 15. Density and flow properties of spray-dried powders comprising a fixed dose combination of nintedanib and ensifentrine
[0233] The impact of the addition of PFOB on bulk and tapped densities is striking (comparing Composition D and Composition E), with dramatic decreases in bulk density observed for the suspension (0.0488 vs. 0.1806 g / cm3). The decreased density leads to improvements in powder flowability, as reflected in decreases in Carr’s Index from 36.9 (very cohesive with very poor powder flow) to 22.0 (passable powder flow). Similarly, the solution ofComposition G also had a low bulk density (0.0382 g / cm3, poor powder flow), while the leucine-based formulation also had a low density in comparison with the phospholipid formulation without PFOB (0.0674 g / cm3, passable powder flow). To put the flowability data in perspective, passable powder flow of fine particles for inhalation is conducive to precise and accurate filling with drum fillers and good to excellent aerosol performance. In addition, and while not illustrated, there is a significant difference in color for the formulations comprising nintedanib base (light yellow) vs. nintedanib esylate (bright yellow), where the esylate salt form of nintedanib was formulated.Example 11 - Particle Size Distribution for the Dry Powders of Example 2
[0234] Primary particle size distributions of the four spray-dried powders were determined by laser diffraction (Table 16). For powders spray-dried from emulsion-based feedstocks (Compositions D, E, and G), the primary particle size distributions are within expectation. In contrast, the primary particle size of the suspension-based powder (Composition F) is significantly larger with D-50=3.57 pm and D-90=8.56 pm.Table 16. Primary particle size distributions of selected spray-dried powders comprising a fixed dose combination of nintedanib and ensifentrine.Example 12 - X-Ray Powder Diffraction Patterns for the Dry Powders of Example 2
[0235] The physical form of the drug in the spray-dried formulations was determined by X-Ray Powder Diffraction (XRPD). Figure 7 shows an overlay of the X-ray powder patterns of spray-dried powder Composition D and ensifentrine and nintedanib free base drug substances. The colored, dashed vertical lines indicate the diffraction peaks of the given drug substance that are observed in the spray-dried powder, indicating that the spray-dried powder contains both crystalline ensifentrine and nintedanib free base. This would be expected for a powder spray-dried from a feedstock in which both drugs are suspended as crystals. The peak at 5.1 °20 is attributed to gel-phase phospholipid.
[0236] Figure 8 shows an overlay of the X-ray powder patterns of spray -dried powder Composition E with X-ray patterns for ensifentrine and nintedanib free base overlayed for clarity. The colored, dashed vertical lines indicate the diffraction peaks of the given drug substance that are observed in the spray-dried powder, indicating that the spray -dried powder contains both crystalline ensifentrine and nintedanib free base. This would be expected for a powder spray-dried from a feedstock in which both drugs are suspended as crystals. The peak at 5.1°20 is attributed to gel-phase phospholipid.
[0237] Figure 9 shows an overlay of the X-ray powder patterns of spray-dried powder Composition F and ensifentrine and nintedanib free base drug substances. The colored, dashed vertical lines indicate the diffraction peaks of the given drug substance that are observed in the spray -dried powder, indicating that the spray -dried powder contains both crystalline ensifentrine and nintedanib free base. This would be expected for a powder spray-dried from a feedstock in which both drugs are suspended as crystals. The major peaks at 5.9 and 19. O°20 are attributed to crystalline leucine.
[0238] Figure 10 shows an overlay of the X-ray powder patterns of spray -dried powder Composition G and reference patterns of ensifentrine, nintedanib free base, and NES drug substances. The colored, dashed vertical lines indicate the diffraction peaks of the givendrug substance that are observed in the spray-dried powder. With the exception of a weak peak at 9. O°20, all peaks can be assigned to ensifentrine or phospholipid (5.2°20).
[0239] Of interest is whether the nintedanib base or salt present in this powder is crystalline or amorphous. While the peak at 9. O°20 indicates that free base could be present (arising from disproportionation of the esylate salt), the peak is quite weak. When comparing the powder patterns of the Example 2 powders, it is clear that Composition G is qualitatively the least crystalline, as given by the lower number and intensity of drug-related diffraction peaks. It is likely that this is due to dissolution of NES in the feedstock, resulting in primarily amorphous NES in this formulation. Although the ensifentrine drug loading in this formulation (8.2% w / w) was about threefold lower than that of NES (25.7% w / w), crystalline ensifentrine was much more easily detected via XRPD. Again, this likely arises from the dissolution of NES in the feedstock.
[0240] A compilation of X-ray powder patterns for compositions D, E, F, and G are provided in Figure 11.Example 13 - Aerosol Performance for Selected the Dry Powders
[0241] Aerodynamic particle size distributions (aPSD) were evaluated using a Next Generation Impactor (NGI). This work focused on fixed-dose combination powders (Compositions D and F), both representing a suspension-based approach. The aPSD plots of each drug in each formulation are shown in Figures 15-18.
[0242] For this example, a 6.5 mg target fill mass was used, corresponding to a fill volume of about 50% of the capsule. The emitted dose of both powders was 89-93%. Due to fixed losses in the capsule and device, these emitted dose values would be expected to increase further if a higher fill mass is used. Mass median aerodynamic diameter (MMAD) values were derived by cumulative undersize interpolation across aerosol stages using stage-specific aerodynamic cut-off diameters, with device, capsule, throat, and micro-orifice collector (MOC) excluded from the analysis. Using this approach, MMAD values ranged from 1.72 - 2.21 pm for ensifentrine and 1.69 - 2.16 pm for nintedanib across the two compositions (see Table 17 below). Within each lot, the MMAD values for ensifentrine and nintedanib were similar, indicating comparable aerodynamic behavior of both components. Based on these results, both drugs would have comparable delivery to the lungs, as would be expected for a formulation in which each particle statistically contains both drugs. The massmedian impaction parameters (MMIPs) were low (133 to 228 pm2L / min), indicative of efficient delivery into the lung periphery, which is critical for treating restrictive lung disease. Table 17
[0243] Key aerosol performance metrics are shown in Table 18 and Figure 12. Two measures of fine particle dose (FPD) based on stage groupings (i.e., impaction parameters) are reported here. Although cascade impactors are not lung simulators and deposition of particles in the lungs, such is more complex than what a simple impactor can discern.However, impactor data can provide high-level guidance on how differences in formulations may impact deposition in the respiratory tract for an average subject. FPD -1 represents the total mass of drug from Stage 3 to the filter and is taken here as an in vitro metric for total deposition in the lungs. FPDs-pis 72-76% (-80% of the ED) for Composition D and 62-64% (-70% of the ED) for Composition F (Table 18) indicative of high-efficiency aerosol delivery. Given that both drugs are formulated within the same particle, it is not surprising that comparable delivery occurs for both drugs in each of the two formulations evaluated. For some fixed dose combinations, co-location of the two drugs (e.g., in Advair) has been proposed as being advantageous for maximizing efficacy. FPD4-r represents the total mass of drug from Stage 4 to the filter and is taken here as representing total deposition in the small airways and alveolar regions (d„Q cutoff -467 pm2L / min). This is perhaps a more relevant metric for drugs focused on treating restrictive lung diseases (e.g., IPF). FPD4-Fis 52-56% for Composition D and 40-42% for Composition F, which is also indicative of high-efficiency aerosol delivery. As was observed with FPD3-, FPD4-F results show that comparable delivery occurs for both drugs in each of the two formulations evaluated.Table 18. Aerosol performance metrics for batches Compositions D and F
[0244] As noted above, the dose of ensifentrine is 0.614 mg while the dose of nintedanib is 1.6 mg. It is worthwhile evaluating the data presented here in the context of these target lung doses. For Composition D, the FPDa-i is 409 pg and 1100 pg for ensifentrine and nintedanib, respectively. However, this was for a 6.5 mg fill mass. The use of a 10 mg fill mass would readily enable achievement of the above target lung doses. Even higher doses could be achieved with further increases in fill mass afforded by use of automated filling equipment (e.g., powder densification using a drum filler). These data indicate that therapeutic doses of both molecules could be delivered via administration of a single capsule. A similar analysis can be conducted for Composition F. Given that it has a lower delivery efficiency, a greater fill mass (e.g., 13 mg) would be required to achieve the above target lung doses. Note also that drug loading could be increased to enable a higher lung dose.
[0245] As described above, these drugs were formulated at a target mass ratio of ensifentrine to nintedanib (E: N) of 0.38 w / w. The actual mass ratios of ensifentrine to nintedanib in the bulk powders were 0.40 Composition D and 0.34 Composition E. HPLC analysis of the powder deposited on each stage of the NGI shows a consistent ensifentrine:nintedanib mass ratio across aerosol deposition to Stage 5 (Figure 13).
[0246] The 8 stages include 7 collection stages and an additional micro-orifice collector (MOC). Each stage is crucial for measuring how particles deposit in the lungs during drug testing and are provided in Table 19 below:Table 19Stage No. Function1 Initial collection of larger particles2 Further collection of medium-sized particles3 Collection of smaller particles4 Continued collection of fine particles5 Collection of very fine particles6 Capture of ultra-fine particles7 Final collection stage for the smallest particlesMOC Micro-orifice collector for precise measurement of very fine particles
[0247] Stage 6 to MOC had lower deposited masses and were nearer the limit of quantification, leading to more variability in the calculated ratio. Overall, the data support a consistent drug ratio in the aerosols, with no evidence of segregation or preferential deposition of either component across the impactor stages. This would be expected such formulations, in which each particle statistically contains both drugs.
[0248] A study was also conducted to assess the deposition of powder in the device. Device retention was calculated on a drug-specific basis using chemical assay measurements of ensifentrine and nintedanib recovered from the device following actuation. The percent deposition of each drug was calculated from the amount of drug loaded into the capsule, as given by the fill mass and assay value of the bulk powder. Results are provided in Table 20. For compositions with replicate testing (Compositions D and F), mean values and standard error of the mean (SEM) are reported. For compositions with single measurements (Compositions E and G), values are reported without error bars. In most cases, the device retention is low and within expectations. In contrast, the device retention of Composition E is markedly higher. This powder was prepared without PFOB and it is possible that reduced porosity adversely affected powder flow and fluidization (note that there are no aPSD data for this Composition).Table 20 Device deposition of Compositions D, E, F, and GExample 14 - Accelerated Temperature Stability Study
[0249] An accelerated stability study was conducted on selected fixed-dose combination powders of Example as well as one ensifentrine monotherapy (Composition A) and one nintedanib monotherapy (Composition C-3), both of Example 1. Each sample consisted of bulk powders in glass vials overwrapped with a foil pouch containing a 1-gram sachet of desiccant. These pouches were stored in a stability oven at 60°C for two months. Given that the powders were stored in glass vials and overwrapped with a strong moisture barrier, the effect of relative humidity is negligible. Thus, this is considered to be solely a thermal study. Stability results are shown in Table 21 and Figure 14.
[0250] Before discussing these results, it’s worthwhile providing context. By design, the storage temperature used in this study was selected to induce degradation to enable formulation screening over months-long timescales. In contrast, pharmaceutical stability studies are most commonly studied over longer timescales at milder conditions such as 25°C / 60%RH and 40°C / 75%RH. Typically, one seeks two years of stability at 25°C / 60%RH and six months at 40°C / 75%RH. If this four-fold reaction rate change is modeled assuming Arrhenius kinetics, one can estimate the implied activation energy. This can then be used to extrapolate the reaction rate at a storage temperature of 60°C. Based on this approach, the degradation rate at 60°C would be about 20-fold higher than at 25°C.
[0251] These results comprise assay values; impurities and degradation products were not measured in this work. Each data set in Figure 14 is annotated with the relative % decrease in assay at the two-month timepoint. The relative loss of ensifentrine ranged between 6 and 12% over two months at 60°C, with the greatest decrease observed for Compositions E and G. The highest stability ensifentrine formulation was the monotherapy, which suggests that the presence of nintedanib might be driving chemical degradation.Ensifentrine in Composition G has slightly better stability than the other two fixed dose combinations, perhaps due to a lower pH arising from the use of the esylate salt form of nintedanib in Composition G.
[0252] Note that, when placed in the context of the above ‘Arrhenius analysis’, 8% degradation of ensifentrine at 60°C would be akin to roughly 0.4% degradation at 25°C overthe same time period. It is also possible that assessment at 60°C promotes degradation pathways that are less dominant at milder temperatures.
[0253] The relative loss of nintedanib ranged between 5 and 17% over two months at 60°C, with the greatest decrease observed for Composition C-3, the monotherapy formulated with nintedanib free base (Figure 14). The nature of the decline is interesting, as the slope increases markedly at the one-month timepoint. In contrast, the fixed-dose combinations that also used nintedanib free base, Compositions E and F showed less degradation. One possibility is that the nintedanib free base DS used in the monotherapy (PB251203-3C) has a different impurity profile than that used for the fixed dose combination work. Nintedanib in the three fixed dose combination powders had between 5.4 and 7.4% relative degradation at 60°C. The lowest degradation was the powder formulated with nintedanib esylate, Composition G. If this trend is statistically significant, then it is somewhat surprising that nintedanib esylate has greater stability than the free base even though it (esylate) partially dissolves in the feedstock and is partially amorphous in the spray-dried particles.
[0254] When placed in the context of the above ‘Arrhenius analysis’, 5% degradation at 60°C would be akin to roughly 0.25% degradation at 25°C over the same time period.Table 21 - Assay results (% w / w) of ensifentrine and nintedanib powders stored at accelerated conditions, 60°C.
[0255] Based on the above, compositions described herein are deemed to be “thermally stable” if they exhibit less than 8% degradation of the active or actives at 60°C over a 1 -month period under this accelerated thermal stability test.
[0256] The above examples demonstrate that fixed-dose combination particle compositions of nintedanib and ensifentrine can be made and that these compositions will deliver both drugs to the lungs at high efficiency. Therapeutically relevant doses could be delivered to the lungs via administration of the contents of a single #3 capsule using aportable, passive dry powder inhaler. Formulation of these dmgs as crystalline solids is expected to provide high physical stability to the spray-dried particles.Example 15 - Preparation of Nintedanib free base
[0257] Nintedanib free base was prepared by deliberate disproportionation of crystalline nintedanib esylate (NES). Disproportion was induced by suspension of NES in an aqueous zwitterionic buffer adjusted to mildly basic pH. Under these conditions, the esylate salt disproportionated and the free base formed directly as a solid phase. Conversion was rapid and reproducible and proceeded equivalently whether the esylate was buffered directly or first dissolved and subsequently re-buffered, indicating tolerance to processing order. Zwitterionic buffering was required for successful conversion; higher ionic strength buffer systems did not promote free base formation and instead maintained the salt in solution. Following conversion, the solid free base was separated by centrifugation, and the isolated solids were diluted and rinsed with reverse osmosis / deionized (RO / DI) water to remove residual buffer salts. Use of zwitterionic buffers produced larger, more readily separable free base solids, which improved recovery during centrifugation and washing. The overall process was operationally robust and not sensitive to minor handling variations. A stepwise procedure is provided below.Materials:• MOPS (3-(N-morpholino)propanesulfonic acid), MilliporeSigma, 186260-25G, lot# 0000496253• NaOH ( 1 N) RICCA, 7450- 16Procedure:1. Dissolve 10.46 g of MOPS (0.05 M) in 1000 mL RODI water at 25°C until clear.2. Measure pH (expected pH4 to pH6).3. Add IN NaOH dropwise while stirring (20 °C) to adjust to pH 7.5-8.0.4. Record mass or volume of IN NaOH solution added.5. Aliquot 200ml of pH-adjusted MOPS buffer into a beaker.6. Add 5.0 g nintedanib mesylate into the aliquot.7. High-shear mix using an IKA T25 for a few minutes; confirm pH > 6.4.8. Use a centrifuge to separate solids from liquid. Rinse isolated solids with RODI water to wash away any remaining esylate and buffer salts into waste while retaining solids. Repeat until solids accumulate in one suspended concentrate (aqueous) and place in drying oven atlow 50°C until dry (2-3 hours). Collect dried material and use mortar and pestle to grind to powder to be used in formulations.Embodiments
[0258] Embodiment 1 - a dry powder composition suitable for direct pulmonary delivery, which comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent.
[0259] Embodiment 2 - a dry powder composition suitable for direct pulmonary delivery, which comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is selected from ensifentrine, HSK39004 / AN01, HRS-9821 / GSK6582701, and TQC3721.
[0260] Embodiment 5 - a dry powder composition suitable for direct pulmonary delivery, which comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof.
[0261] Embodiment 4-a dry powder composition suitable for direct pulmonary delivery, which comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof.
[0262] Embodiment 5 - a dry powder composition suitable for direct pulmonary delivery, which comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof.
[0263] Embodiment 6- a dry powder composition suitable for direct pulmonary delivery, which comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof.
[0264] Embodiment 7 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the anti-fibrotic agent is selected from nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, and pirfenidone, or a pharmaceutically acceptable salt of each of these.
[0265] Embodiment 8 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and one or more anti-fibrotic agents, wherein the one or more anti-fibrotic agents is / are selected fromnintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, and pirfenidone, or a pharmaceutically acceptable salt of each of these.
[0266] Embodiment 9 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is nintedanib or a pharmaceutically acceptable salt thereof.
[0267] Embodiment 10 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is treprostinil or a pharmaceutically acceptable salt thereof.
[0268] Embodiment 11 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is treprostinil palmitil.
[0269] Embodiment 12 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is pirfenidone.
[0270] Embodiment 13 - d dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is deupirfenidone.
[0271] Embodiment 14 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is nintedanib or a pharmaceutically acceptable salt thereof.
[0272] Embodiment 15 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceuticallyacceptable salt thereof and the anti-fibrotic agent is treprostinil or a pharmaceutically acceptable salt thereof.
[0273] Embodiment 16 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is treprostinil palmitil.
[0274] Embodiment 17 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is pirfenidone.
[0275] Embodiment 18 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is deupirfenidone.
[0276] Embodiment 19 - dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is nintedanib or a pharmaceutically acceptable salt thereof.
[0277] Embodiment 20 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is treprostinil or a pharmaceutically acceptable salt thereof.
[0278] Embodiment 21 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is treprostinil palmitil.
[0279] Embodiment 22 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is pirfenidone.
[0280] Embodiment 23 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is deupirfenidone.
[0281] Embodiment 24 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is nintedanib or a pharmaceutically acceptable salt thereof.
[0282] Embodiment 25 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is treprostinil or a pharmaceutically acceptable salt thereof.
[0283] Embodiment 26 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is treprostinil palmitil.
[0284] Embodiment 27 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is pirfenidone.
[0285] Embodiment 28 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof and the anti-fibrotic agent is deupirfenidone.
[0286] Embodiment 29 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc: or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0287] Embodiment 30 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof, and wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc.
[0288] Embodiment 31 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; and further wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc.
[0289] Embodiment 32 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof, and further wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc.
[0290] Embodiment 33 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have an median particle size of from about 0.5 pm to about 15 pm.
[0291] Embodiment 34 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0292] Embodiment 35 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0293] Embodiment 35 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0294] Embodiment 37 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0295] Embodiment 38 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0296] Embodiment 39- a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0297] Embodiment 40 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0298] Embodiment 41 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0299] Embodiment 42 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; wherein said drypowder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0300] Embodiment 43 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0301] Embodiment 44- a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0302] Embodiment 45 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof, and wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0303] Embodiment 46 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof, and wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc.
[0304] Embodiment 47 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; and further wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc.
[0305] Embodiment 48 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof, and furtherwherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc.
[0306] Embodiment 49 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0307] Embodiment 56 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0308] Embodiment 51 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0309] Embodiment 52 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0310] Embodiment 53 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0311] Embodiment 54 - dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; andfurther wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0312] Embodiment 55 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0313] Embodiment 56 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0314] Embodiment 57 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0315] Embodiment 58 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0316] Embodiment 59 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0317] Embodiment 60 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0318] Embodiment 61 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof, and wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0319] Embodiment 62 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof, and wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc.
[0320] Embodiment 63 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; and further wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc.
[0321] Embodiment 64 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof, and further wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc.
[0322] Embodiment 65 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0323] Embodiment 66 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0324] Embodiment 67 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0325] Embodiment 68 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0326] Embodiment 69 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0327] Embodiment 70 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0328] Embodiment 71 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc;and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0329] Embodiment 72 - a dry powder composition suitable for direct pulmonary delivery, which HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0330] Embodiment 73 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0331] Embodiment 74 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0332] Embodiment 75 A dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0333] Embodiment 76 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0334] Embodiment 77 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof, and wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0335] Embodiment 78 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof, and wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc.
[0336] Embodiment 79 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; and further wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc.
[0337] Embodiment 80 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof, and further wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc.
[0338] Embodiment 81 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0339] Embodiment 82 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0340] Embodiment 83 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0341] Embodiment 84 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0342] Embodiment 85 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0343] Embodiment 86 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0344] Embodiment 87- a. dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0345] Embodiment 88 - a dry powder composition suitable for direct pulmonary delivery, which TQC3721 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0346] Embodiment 89 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0347] Embodiment 90 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0348] Embodiment 91 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof: wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0349] Embodiment 92 - a dry powder composition suitable for direct pulmonary delivery, which composition comprises a PDE3 / PDE4 inhibitor, wherein the PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof; wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0350] Embodiment 93 - dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0351] Embodiment 94- a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc.
[0352] Embodiment 95 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc.
[0353] Embodiment 96- a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc.
[0354] Embodiment 97 - dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0355] Embodiment 98 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0356] Embodiment 99 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0357] Embodiment 100 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0358] Embodiment 101 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0359] Embodiment 1023 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0360] Embodiment 103 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0361] Embodiment 104 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein saidparticles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0362] Embodiment 105 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0363] Embodiment 106 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0364] Embodiment 107 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0365] Embodiment 108 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 9-13, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0366] Embodiment 109 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0367] Embodiment 110 - a. dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc.
[0368] Embodiment 111 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc.
[0369] Embodiment 112 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc.
[0370] Embodiment 113 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said particles in said powder composition have a median particle size of from about 0.5 µm to about 15 µm.
[0371] Embodiment 114 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0372] Embodiment 115 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0373] Embodiment 116 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0374] Embodiment 117 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0375] Embodiment 118 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0376] Embodiment 119 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0377] Embodiment 120 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0378] Embodiment 121 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0379] Embodiment 122 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0380] Embodiment 123 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0381] Embodiment 124 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0382] Embodiment 125 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0383] Embodiment 126 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc.
[0384] Embodiment 127 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc.
[0385] Embodiment 128 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc.
[0386] Embodiment 129 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 14-18, wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0387] Embodiment 130 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0388] Embodiment 131 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23 wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0389] Embodiment 132 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0390] Embodiment 133 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0391] Embodiment 134 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0392] Embodiment 135 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein saidparticles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0393] Embodiment 136 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0394] Embodiment 137 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0395] Embodiment 138 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0396] Embodiment 139 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0397] Embodiment 140 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 19-23, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0398] Embodiment 141 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28, wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0399] Embodiment 142 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28 wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0400] Embodiment 143 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0401] Embodiment 144 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0402] Embodiment 145 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0403] Embodiment 146 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0404] Embodiment 147 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0405] Embodiment 148 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0406] Embodiment 149 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein saidparticles in said powder composition have a median particle size of from about 0.5 pm to about 15 pm.
[0407] Embodiment 150 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 10 pm.
[0408] Embodiment 151 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 24-28, wherein said dry powder composition has a bulk density of from about 0.05 g / cc to about 0.09 g / cc; and further wherein said particles in said powder composition have a median particle size of from about 0.5 pm to about 5 pm.
[0409] Embodiment 152 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 1-151, wherein the composition comprises no more than about 6 weight percent water.
[0410] Embodiment 153 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 1-151, wherein the composition comprises no more than about 4 weight percent water.
[0411] Embodiment 154 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 1-151, wherein said dry powder composition further comprises: c) a lecithin compound such as a di-fatty acid phosphatidylcholine, and d) a divalent cation (e.g., calcium or magnesium chloride).
[0412] Embodiment 155 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 1-154, which is thermally stable.
[0413] Embodiment 156 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 9 in combination with any one of Embodiments 83-108 and / or Embodiments 152-155 solely as they relate to Embodiment 9 (i.e., a dry powder composition comprising both ensifentrine or a pharmaceutically acceptable salt thereof and nintedanib as the base or as a pharmaceutically acceptable salt).
[0414] Embodiment 157 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 156, wherein nintedanib is a base (no salt).
[0415] Embodiment 158 - a dry powder composition suitable for direct pulmonary delivery comprising ensifentrine or a pharmaceutically acceptable salt thereof and a nintedanib salt.
[0416] Embodiment 159 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 157, wherein the nintedanib salt is the esylate salt
[0417] Embodiment 160 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 156 -159, wherein the relative weight ratio of a) ensifentrine (independent of the salt if administered as a pharmaceutically acceptable salt) to b) nintedanib (also independent of the salt if administered as a pharmaceutically acceptable salt) is from about 0.125:1 to about 5: 1 (about 1:8 to about 5:1).
[0418] Embodiment 161 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 160, wherein the pharmaceutically acceptable salt of nintedanib is nintedanib esylate; and, the pharmaceutically acceptable salt of ensifentrine is ensifentrine hydrochloride.
[0419] Embodiment 162 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161, wherein nintedanib is its nintedanib base; and, ensifentrine is ensifentrine hydrochloride.
[0420] Embodiment 163 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161, wherein the pharmaceutically acceptable salt of nintedanib is nintedanib esylate; and the pharmaceutically acceptable salt of ensifentrine is ensifentrine hydrochloride.
[0421] Embodiment 164 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib,wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc;wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm or from about 0.5 to about 10.0 pm; or from about 0.5 to about 5.0 pm; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water or no more than about 4 weight percent water.
[0422] Embodiment 165 - a dry powder composition suitable for direct pulmonary delivery according o Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib,wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water.
[0423] Embodiment 166 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water.
[0424] Embodiment 167 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib,wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water.
[0425] Embodiment 168 - a dry powder composition suitable for direct pulmonary delivery according o Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib.wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 10 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water.
[0426] Embodiment 169 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 5 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water.
[0427] Embodiment 170 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib,wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 10 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water.
[0428] Embodiment 171 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 5 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water.
[0429] Embodiment 172 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 10 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water.
[0430] Embodiment 173- a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 5 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water.
[0431] Embodiment 174 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 4 weight percent water.
[0432] Embodiment 175 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.15 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 4 weight percent water.
[0433] Embodiment 176 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.04 g / cc to about 0.11 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 4 weight percent water.
[0434] Embodiment 177 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 10 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water.
[0435] Embodiment 178 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 5 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 4 weight percent water.
[0436] Embodiment 179 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 10 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 4 weight percent water.
[0437] Embodiment 180 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 5 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 4 weight percent water.
[0438] Embodiment 181 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 10 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 4 weight percent water.
[0439] Embodiment 182 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 161 or Embodiment 162,wherein said dry powder comprises a) ensifentrine, and b) nintedanib, wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc,wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 5 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1; andfurther wherein the dry powder as described herein comprises no more than about 4 weight percent water.
[0440] Embodiment 183 - a dry powder composition suitable for direct pulmonary delivery according to any one of Embodiments 1 through 182, wherein said composition further comprises one or more pharmaceutically acceptable additives, selected from a dispersing agent, a buffering agent, a disaccharide, an antioxidant, a stabilizer, and any combination thereof, wherein the dispersing agent is selected from leucine, trileucine, and a combination of leucine and trileucine, and each or any combination of such agents can optionally include a further dispersing agent.
[0441] Embodiment 184 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 183, wherein said dispersing agent is polyethylene glycol sorbitan monooleate.
[0442] Embodiment 185 - a dry powder composition suitable for direct pulmonary delivery according to Embodiment 183 or Embodiment 184, wherein said buffering agent is an acetate, citrate, phosphate, tartrate, and / or triethanolamine buffer.
[0443] Embodiment 186 - a device suitable for administration by inhalation, wherein said device comprises a dry powder composition according to any one of Embodiments 1-154.
[0444] Embodiment 187 - a device suitable for administration by inhalation according to Embodiment 186, wherein said device is selected from a nebulizer, a pressurized metered dose inhaler (pMDI), or a dry powder inhaler (DPI).
[0445] Embodiment 188 - a method for delivering a composition according to any one of Embodiments 1-182 to the deep pulmonary tract, while not using a low resistance device, by undertaking a slow and deep inhalation at a flow rate of from about 25 to 35 liters per minute (LPM) coupled with the use of ultra-low density powders (densities of about 0.10 g / cc3or less) and having diameters of about 0.15 microns or less, thereby enhancing the delivery of medicament into the deep pulmonary tract of the patient; optionally achieving an MMIP value less than 500 pm2L / min, less than 400 pm2L / min, or less than 300 pm2L / min.
[0446] Embodiment 189 - a method for treating a patient diagnosed with pulmonary fibrosis (PF), which method comprises:administering by inhalation to the lungs of the patient a dry powder composition according to any one of Embodiments 1-182,wherein said PF is selected from an interstitial lung disease, a progressive fibrosing interstitial lung disease, a systemic sclerosis-associated interstitial lung disease, or anidiopathic pulmonary fibrosis, and pulmonary fibrosis; optionally, wherein the PF is idiopathic pulmonary fibrosis.
[0447] Embodiment 190 - the method of Embodiment 189, wherein the PF is idiopathic pulmonary fibrosis.
[0448] Embodiment 191 - the method of Embodiment 189 or Embodiment 190, wherein said patients diagnosed with stage 1 or stage 2 pulmonary fibrosis (PF) are qualified for treatment; and said patients diagnosed with stage 3 or stage 4 PF are disqualified from treatment.
[0449] Embodiment 192 - the method of Embodiment 191, wherein treatment for said qualified patients is initiated using a dry powder composition comprising ensifentrine or the pharmaceutically acceptable salt and an anti-fibrotic agent selected from an effective amount of nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, pirfenidone, and deupirfenidone, or a pharmaceutically acceptable salt of each of these, provided that pirfenidone and deupirfenidone do not form salts;monitoring said qualified patient before and after treatment is initiated to determine the extent of progression of said disease in each of said patients after initiating pharmacotherapy as compared to prior to treatment and determining whether an inflection point is identified, evidencing that the slope in the rate of disease progression has changed from a higher angle on the X and Y axis to a lower angle; andoptionally removing patients from pharmacotherapy for whom the attending clinician determines that further treatment is no longer effective.
[0450] Embodiment 193 - a dry powder composition comprising a PDE3 / PDE4 inhibitor or pharmaceutically acceptable salt thereof, which dry powder composition comprises:an inhibitor is selected from HSK39004 / AN01, HRS-9821 / GSK6582701, and TQC3721, each optionally as a pharmaceutically acceptable salt thereof, wherein said inhibitor is the sole PF medicament therein;wherein said dry powder composition comprises particles having a median particle size of from about 0.5 to about 15 pm; or from about 0.5 to about 10 pm; or from about 0.5 to about 5 pm,an ultra bulk density of from about 0.03 g / cc to about 0.15 g / cc, from about 0.04 g / cc to about 0.11 g / cc, from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc;wherein said dry powder composition has a water content of no more than about 6 weight percent water; andfurther wherein said composition is suitable for treating PF.
[0451] Embodiment 194 - a dry powder composition comprising an anti-fibrotic agent or a pharmaceutically acceptable salt thereof, which dry powder composition comprises:an anti-fibrotic agent selected from nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, pirfenidone, and deupirfenidone, or, where appropriate, a pharmaceutically acceptable salt thereof, wherein said anti-fibrotic agent is the sole PF medicament therein;wherein said dry powder composition comprises particles having a median particle size of from about 0.5 to about 15 pm; or from about 0.5 to about 10 pm; or from about 0.5 to about 5 pm,an ultra bulk density of from about 0.03 g / cc to about 0.15 g / cc, from about 0.04 g / cc to about 0.11 g / cc, from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc;wherein said dry powder composition has a water content of no more than about 6 weight percent water; andfurther wherein said composition is suitable for treating PF.
[0452] Embodiment 195 - a dry powder composition of either Embodiment 193 or Embodiment 194, which further comprises an effective amount of distearoylphosphatidylcholine and an effective amount of magnesium chloride or calcium chloride.Embodiment 196 - a dry powder composition comprising an effective amount of ensifentrine or a pharmaceutically acceptable salt thereof, and nintedanib or a pharmaceutically acceptable salt thereof, wherein the composition is suitable for being administered by inhalation, and wherein the relative weight ratio of a) ensifentrine or the pharmaceutically acceptable salt thereof to b) nintedanib or a pharmaceutically acceptable salt thereof in the composition is from about 0.125:1 to about 5:1.
[0453] Embodiment 197 - the dry powder composition of Embodiment 196, wherein the pharmaceutically acceptable salt of nintedanib is nintedanib esylate, and wherein the pharmaceutically acceptable salt of ensifentrine is ensifentrine hydrochloride.
[0454] Embodiment 198 - a dry powder composition according to any one of Embodiments 1 to 185 and 193-196, wherein the composition is suitable for being administered by a nebulizer, a pressurized metered dose inhaler (pMDI), or a dry powder inhaler (DPI).
[0455] Embodiment 199 - a dry powder composition according to Embodiment 193 or Embodiment 196, wherein the composition is a dry powder composition having a bulk density of from about 0.03 g / cc to about 0.30 g / cc, from about 0.04 g / cc to about 0.10 g / cc, from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0456] Embodiment 200 - a dry powder composition according to Embodiment 199, wherein the dry powder composition further comprises a phosphatidylcholine and calcium chloride.
[0457] Embodiment 201 - a dry powder composition according to any one of Embodiments 1 to 185 and 193-200, wherein said ensifentrine or the pharmaceutically acceptable salt thereof and / or said nintedanib or the pharmaceutically acceptable salt thereof are uniformly dispersed in said dry powder composition.
[0458] Embodiment 202 - a dry powder composition according to Embodiments 193 to 201, wherein said dry powder composition comprises particles having a median particle size of from about 0.5 pm to about 15 pm.
[0459] Embodiment 203 - a dry powder composition according to Embodiment 202, wherein the relative weight ratio of ensifentrine or the pharmaceutically acceptable salt thereof to nintedanib or a pharmaceutically acceptable salt thereof in the dry powder composition is from about 3:4 to about 3:8 based on the free base of both ensifentrine and nintedanib.
[0460] Embodiment 204 - a dry powder composition suitable for direct pulmonary administration, wherein said dry powder composition comprises:an effective amount of i) ensifentrine or a pharmaceutically acceptable salt thereof and ii) nintedanib or a pharmaceutically acceptable salt thereof;an effective amount of distearoylphosphatidylcholinephosphatidylcholine; and an effective amount of calcium chloride;and, wherein said powder composition comprises particles having a median particle size of from about 0.5 to about 15 pm and a bulk density of from about 0.03 g / cc to about 0.30 g / cc, from about 0.04 g / cc to about 0.10 g / cc, from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
[0461] Embodiment 205 - a dry powder composition according to Embodiment 204, wherein ensifentrine or the pharmaceutically acceptable salt thereof, and nintedanib or the pharmaceutically acceptable salt thereof are uniformly dispersed throughout in a ratio proportional to the amount of each used in said dry powder composition on a weight basis.
[0462] Embodiment 206 - a dry powder composition according to Embodiment 205, wherein the relative weight ratio of i) ensifentrine or the pharmaceutically acceptable salt thereof to ii) nintedanib or the pharmaceutically acceptable salt thereof in said dry powder composition is from about 0.125:1 to about 5:1, or from about 3:4 to about 3:8.
[0463] Embodiment 207 - a dry powder composition according to Embodiments 1 to 185 and 193-206, wherein said composition further comprises one or more pharmaceutically acceptable additives.
[0464] Embodiment 208 - a dry powder composition according to Embodiment 207, wherein said one or more pharmaceutically acceptable additives are selected from a dispersing agent, a buffering agent, a disaccharide, an antioxidant, a dispersing agent, a stabilizer, and any combination thereof.
[0465] Embodiment 209 - a dry powder composition according to Embodiment 208, wherein said additive is a dispersing agent which is selected from leucine, trileucine, and a combination of leucine and trileucine, and each or the combination optionally in the presence of a further dispersing agent.
[0466] Embodiment 210 - a dry powder composition according to Embodiment 209, wherein said further dispersing agent is polyethylene glycol sorbitan monooleate.
[0467] Embodiment 211 - a dry powder composition according to Embodiment 210, wherein said additive is a buffering agent which is a biocompatible buffer, optionally an acetate, citrate, phosphate, tartrate, and / or triethanolamine buffer.
[0468] Embodiment 212 - a dry powder composition according to Embodiment 210, wherein said additive is a disaccharide such as trehalose or lactose (anhydrate or monohydrate).
[0469] Embodiment 213 - a dry powder composition according to Embodiment 210, wherein said additive is an antioxidant which is selected from ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, cysteine, glutathione, propyl gallate, sodium metabisulfite, sodium thiosulfate, and vitamin E.
[0470] Embodiment 214 - a dry powder composition according to Embodiment 193 or Embodiment 194, wherein the pharmaceutically acceptable salt of nintedanib is nintedanibesylate. and wherein the pharmaceutically acceptable salt of ensifentrine is ensifentrine hydrochloride.
[0471] Embodiment 215 - a method for treating a patient diagnosed with pulmonary fibrosis (PF), which method comprises administering to the lungs of the patient a dry powder composition which itself comprises particles comprising an effective amount of a pharmaceutical combination of ensifentrine or a pharmaceutically acceptable salt thereof and optionally an effective amount of treprostinil, treprostinil palmitil, treprostinil sodium, or pirfenidone; an effective amount of nintedanib or a pharmaceutically acceptable salt thereof; wherein the particles further comprise a di-fatty acid phosphatidylcholine and calcium chloride in an amount sufficient to impart structural stability; and further wherein said particles in said dry powder composition have a median particle size of from about 0.5 to about 15 pm and the dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, and the PF is as interstitial lung disease, progressive fibrosing interstitial lung disease, systemic sclerosis-associated interstitial lung disease, or idiopathic pulmonary fibrosis and pulmonary fibrosis.
[0472] Embodiment 216- a method according to Embodiment 215, wherein said PF is classified as idiopathic pulmonary fibrosis.
[0473] Embodiment 217 - a method according to Embodiment 215, wherein the pharmaceutically acceptable salt of nintedanib is nintedanib esylate, and wherein the pharmaceutically acceptable salt of ensifentrine is ensifentrine hydrochloride.
[0474] Embodiment 218 - a method for treating a patient diagnosed with pulmonary fibrosis (PF), which method comprises administering an effective amount of the dry powder composition of any one of Embodiments 203 to 214 to the lungs of the patient diagnosed as having PF, wherein the step of administering to the patient is a sequential administration in any order of ensifentrine or the pharmaceutically acceptable salt and nintedanib or the pharmaceutically acceptable salt or a contemporaneous administration of ensifentrine or the pharmaceutically acceptable salt and nintedanib or a pharmaceutically acceptable salt, wherein said dry powder composition comprises particles having a median particle size of from about 0.5 to about 15 pm; said dry powder composition obtained by spray drying has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, and wherein said PF is idiopathic pulmonary fibrosis (IPD), interstitial lung disease, progressive fibrosing interstitial lung disease, or systemic sclerosis-associated interstitial lung disease.
[0475] Embodiment 219- a method according to Embodiment 218, wherein said patient is qualified as having stage 1 or stage 2 PF.
[0476] Embodiment 220 - the method according to Embodiment 218, wherein the patient qualifies as having incipient or moderately developed idiopathic pulmonary fibrosis but is not diagnosed with hypoxic respiratory failure or resting hypoxemia.
[0477] Embodiment 221 - the method according to Embodiment 220, wherein said method reduces disease progression in the patient.
[0478] Embodiment 222 - the method according to Embodiment 218, wherein said method reduces or prevents in the treated patient at least one adverse event associated with an oral administration of nintedanib or the pharmaceutically acceptable salt thereof.
[0479] Embodiment 223 - the method according to Embodiment 222, wherein said at least one adverse event associated with the oral administration of nintedanib or the pharmaceutically acceptable salt thereof is selected from the group consisting of: nausea, a rash, stomach pain, an upper respiratory tract infection, diarrhea, fatigue, a headache, indigestion, dizziness, decreased patient appetite or loss of appetite, gastroesophageal reflux disease (GERD), sinusitis, sleeplessness, weight loss, and joint pain.
[0480] Embodiment 224 - the method according to Embodiment 218, wherein the pharmaceutically acceptable salt of nintedanib is nintedanib esylate, and wherein the pharmaceutically acceptable salt of ensifentrine is ensifentrine hydrochloride.
[0481] Embodiment 225 - a method according to Embodiment 218, wherein said step of administering is continued for the patient if one or more of the symptoms of pulmonary fibrosis have been reduced.
[0482] Embodiment 226 - a method according to Embodiment 218, wherein said symptoms of the patient are reduced compared to symptoms of untreated patients.
[0483] Embodiment 227 - a method according to Embodiment 226, wherein said symptoms are selected from the group consisting of reduced coughing, improved carbon monoxide diffusion capacity, stabilization of dyspnea, and reduced periods of shortness of breath.
[0484] Embodiment 228 - a method according to Embodiment 227, wherein said patient with PF has a forced vital capacity (FVC) of more than about 40% ± 5% and / or a DLCO (lung diffusion capacity for carbon monoxide) of more than about 30% ± 5% predicted.
[0485] Embodiment 229 - a method according to Embodiment 218, wherein said effective amount of the pharmaceutical combination reduces the rate of disease progression in said patient by at least about 10%.
[0486] Embodiment 230 - a method according to Embodiment 218, wherein the effective amount of the pharmaceutical combination reduces the rate of disease progression in said patient by at least about 20%.
[0487] Embodiment 231 - a method according to Embodiment 218, wherein the effective amount of the pharmaceutical combination reduces the rate of disease progression in said patient by at least about 30%.Embodiment 232 - a method according to Embodiment 218, wherein the effective amount of the pharmaceutical combination reduces the rate of disease progression in said patient by at least about 50%.Embodiment 233 - a method according to Embodiment 218, wherein the effective amount of the pharmaceutical combination reduces the rate of disease progression in said patient by at least about 75%.
[0488] Embodiment 234 - a method according to Embodiment 218, wherein ensifentrine or the pharmaceutically acceptable salt thereof is dosed at about 1 mg to 5 mg ensifentrine, administered in a single capsule twice daily; and wherein nintedanib or the pharmaceutically acceptable salt thereof is dosed at about 1 mg to 8 mg nintedanib, administered in a single capsule twice daily.
[0489] Embodiment 235 - A method of making a dry powder composition comprising i) ensifentrine or a pharmaceutically acceptable salt thereof and ii) nintedanib or a pharmaceutically acceptable salt thereof comprising the steps of a) preparing a nanoemulsion comprising perfluorooctyl bromide (PFOB) droplets, wherein the emulsion is stabilized by distearoylphosphatidylcholine (DSPC) b) admixing i) ensifentrine or a pharmaceutically acceptable salt thereof, ii) nintedanib or a pharmaceutically acceptable salt thereof, and c) homogenizing the emulsion-suspension to produce drug particles of the requisite particle size, wherein the nanoemulsion comprises 90% water, and spray drying the nanoemulsion to obtain the powder composition.
[0490] Embodiment 236 - the method of Embodiment 235, wherein said method further comprises adjusting the pH of the admixed nanoemulsion to about 5.3 ± 0.3 and wherein nintedanib or the pharmaceutically acceptable salt thereof is admixed in the emulsionfirst until dissolved, followed by admixing ensifentrine or the pharmaceutically acceptable salt thereof, which is further admixed until dissolved.
[0491] Embodiment 237 - the method of Embodiments 235 or Embodiments 236, wherein the pharmaceutically acceptable salt of nintedanib is nintedanib esylate, and wherein the pharmaceutically acceptable salt of ensifentrine is ensifentrine hydrochloride.
[0492] Embodiment 238 - the method of any one of Embodiments 188 to 192 and 215 to 233, wherein the dry powder composition is administered as a single capsule, optionally the dry powder composition is administered with a single inhalation from a capsule or a blister.
Claims
What is claimed is:
1. A dry powder composition suitable for pulmonary delivery which comprises a combination of a PDE3 / PDE4 inhibitor and an anti-fibrotic agent.
2. The dry powder composition of claim 1, wherein said PDE3 / PDE4 inhibitor is selected from ensifentrine, HSK39004 / AN01, HRS-9821 / GSK6582701, and TQC3721, or a pharmaceutically acceptable salt of each.
3. The dry powder composition of claim 1, wherein said PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof.
4. The dry powder composition of claim 1, wherein said PDE3 / PDE4 inhibitor is HSK39004 / AN01 or a pharmaceutically acceptable salt thereof.
5. The dry powder composition of claim 1, wherein said PDE3 / PDE4 inhibitor is HRS-9821 / GSK6582701 or a pharmaceutically acceptable salt thereof.
6. The dry powder composition of claim 1, wherein said PDE3 / PDE4 inhibitor is TQC3721 or a pharmaceutically acceptable salt thereof.
7. The dry powder composition of any one of claims 1-6, wherein said anti-fibrotic agent is selected from one or more nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, and pirfenidone, or a pharmaceutically acceptable salt.
8. The dry powder composition of claim 1, wherein the PDE3 / PDE4 inhibitor is ensifentrine or a pharmaceutically acceptable salt thereof, and the anti-fibrotic agent is nintedanib or a salt thereof.
9. The dry powder composition of claim 8, wherein said anti-fibrotic agent is a nintedanib salt.
10. The dry powder composition of claim 9, wherein said nintedanib salt is nintedanib esylate.
11. The dry powder composition of claim 1, wherein nintedanib is the free base.
12. The dry powder composition of any one of claims 1-11, wherein said dry powder in said composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc.
13. The dry powder composition of claim 12, wherein said dry powder composition comprises particles having a median particle size of from about 0.5 pm to about 15 pm or from about 0.5 pm to about 10 pm; or from about 0.5 to about 5 pm.
14. The dry powder composition of claim 13, wherein said composition comprises no more than about 6 weight percent water or no more than about 4 weight percent water.
15. The dry powder composition of claim 1, which further comprises: c) a lecithin compound such as a di-fatty acid phosphatidylcholine, and d) a divalent cation.
16. The dry powder composition of claim 13, which further comprises: c) a lecithin compound such as a di-fatty acid phosphatidylcholine, and d) a divalent cation.
17. The dry powder composition of claim 13, wherein the weight ratio of a) ensifentrine to b) nintedanib is from about 0.125: 1 to about 5: 1 based on the free base of each.
18. A dry powder composition which comprises a) ensifentrine or a pharmaceutically acceptable salt thereof, and b) nintedanib or a pharmaceutically acceptable salt thereof,wherein said dry powder composition has a bulk density of from about 0.03 g / cc to about 0.30 g / cc, or from about 0.03 g / cc to about 0.15 g / cc; or from about 0.04 g / cc to about 0.11 g / cc, or from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc;wherein the dry powder composition as described herein comprises particles having a median particle size of from about 0.5 pm to about 15 pm or from about 0.5 to about 10.0 pm; or from about 0.5 to about 5.0 pm,wherein the relative weight ratio of a) ensifentrine to b) nintedanib in the dry powder composition is from about 1:8 to about 5:1, wherein the weight of each is based on the free base thereof; andfurther wherein the dry powder as described herein comprises no more than about 6 weight percent water or no more than about 4 weight percent water.
19. A method for treating a patient diagnosed with pulmonary fibrosis (PF), which method comprises:administering to the lungs of the patient an effective amount of a dry powder composition according to any one of claims 1, 12, and 18,wherein said PF is selected from an interstitial lung disease, a progressive fibrosing interstitial lung disease, a systemic sclerosis-associated interstitial lung disease, an idiopathic pulmonary fibrosis, and pulmonary fibrosis; optionally, wherein the PF is idiopathic pulmonary fibrosis.
20. The method of claim 19, wherein said patient is diagnosed with stage 1 or stage 2 PF but not with stage 3 or stage 4.
21. The method of claim 20, wherein said PF is idiopathic pulmonary fibrosis.
22. The method of claim 19, wherein said method treats a patient with stage 1 or stage 2 PF by stabilizing one or more of the patient’s symptoms associated with PF and / or mitigating the rate of symptom severity and / or frequency as compared to an untreated patient at the same level of disease progression.
23. The method of claim 22, wherein said one or more symptoms stabilized and / or mitigated are selected from coughing, impaired carbon monoxide diffusion capacity, stabilization of dyspnea, and reduced periods of shortness of breath.
24. The method of claim 19, wherein said the dry powder composition is administered as a single capsule, optionally the dry powder composition is administered with a single inhalation from a capsule or a blister.
25. A dry powder composition comprising a PDE3 / PDE4 inhibitor or pharmaceutically acceptable salt thereof, which dry powder composition comprises:an inhibitor is selected from HSK39004 / AN01, HRS-9821 / GSK6582701, and TQC3721, each optionally as a pharmaceutically acceptable salt thereof, wherein said inhibitor is the sole PF medicament therein;wherein said dry powder composition comprises particles having a median particle size of from about 0.5 to about 15 pm; or from about 0.5 to about 10 pm; or from about 0.5 to about 5 pm,a bulk density of from about 0.03 g / cc to about 0.15 g / cc, from about 0.04 g / cc to about 0.11 g / cc, from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc;wherein said dry powder composition has a water content of no more than about 6 weight percent water; andwherein said composition is suitable for treating PF.
26. The dry powder composition of claim 25, which further comprises an effective amount of distearoylphosphatidylcholine and an effective amount of magnesium chloride or calcium chloride.
27. A dry powder composition comprising an anti -fibrotic agent or a pharmaceutically acceptable salt thereof, which dry powder composition comprises:an anti-fibrotic agent selected from nintedanib, treprostinil, treprostinil palmitil, treprostinil sodium, pirfenidone, and deupirfenidone, or, where appropriate, a pharmaceutically acceptable salt thereof, wherein said anti-fibrotic agent is the sole PF medicament therein;wherein said dry powder composition comprises particles having a median particle size of from about 0.5 to about 15 pm; or from about 0.5 to about 10 pm; or from about 0.5 to about 5 pm,a bulk density of from about 0.03 g / cc to about 0.15 g / cc, from about 0.04 g / cc to about 0.11 g / cc, from about 0.05 g / cc to about 0.09 g / cc, or from about 0.06 g / cc to about 0.08 g / cc;wherein said dry powder composition has a water content of no more than about 6 weight percent water; andfurther wherein said composition is suitable for treating PF.
28. The dry powder composition of claim 27, which further comprises an effective amount of distearoylphosphatidylcholine and an effective amount of magnesium chloride or calcium chloride.
